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Zusammenfassung 
Beim klassischen Hodgkin Lymphom (cHL) handelt es sich um eine maligne Erkrankung des 
hämatopoetischen Systems, die durch ein einzigartiges histologisches Muster charakterisiert ist. 
Die Tumormasse ist hauptsächlich aus infiltrierten Lymphozyten und anderen Zellen 
hämatologischen Ursprungs zusammengesetzt, jedoch aus nur sehr wenigen neoplastischen 
Zellen. cHL-Tumorzellen werden durch CD30 als wichtigsten immunologischen Marker 
charakterisiert. Die Mehrheit der Patienten mit cHL in einem frühen Stadium können durch 
Standardtherapie, einer Kombination aus multimodaler Chemotherapie und Radiotherapie, 
behandelt werden. Jedoch sind Behandlungsmöglichkeiten für Patienten, die nicht empfänglich für 
die Standardtherapie sind oder ein Rezidiv erleiden, noch unzureichend. In den letzten Jahren 
haben neue Ansätze für die Behandlung von cHL basierend auf Immuntherapie an Bedeutung 
gewonnen. CD30 ist als Zielmolekül dabei von besonderer Bedeutung, da es auf anderen Zellen nur 
sehr gering exprimiert wird. Onkolytische Viren (OV) kombinieren die selektive Lyse von 
Tumorzellen mit der Induktion einer antitumoralen Immunantwort. Da sie jedoch einen relativ 
breiten Tropismus aufweisen, wurden verschiedene Strategien entwickelt, um die 
Tumorselektivität zu erhöhen. Ein Ansatz basiert auf dem Retargeting des Zelleintritts viraler 
Partikel auf einen bestimmten Rezeptor der Wahl durch genetische Modifikation der viralen Hülle. 
Die vorliegende Arbeit beschäftigt sich mit einer neuartigen Behandlungsstrategie für cHL, die auf 
genetisch modifizierten CD30-targetierten OV beruht. Dazu wurden Masernviren (MV) und 
Vesikuläre Stomatitis Viren (VSV) so verändert, dass sie CD30 als Rezeptor für die Infektion von 
CD30+ cHL Tumorzellen verwenden. MV-CD30 und VSV-CD30 basieren auf einem kürzlich 
beschriebenen CD30-spezifischen Einzelkettenantikörperfragment (scFv) und wurden für diese 
Arbeit zur Verfügung gestellt. Für die Generierung von VSV-CD30 wurde VSV-G deletiert und gegen 
die modifizierten Glykoproteine von MV-CD30 ersetzt. In der vorliegenden Arbeit wurde zunächst 
die spezifische Infektion von zwei verschiedenen CD30+ cHL Tumorzelllinien, L-428 und KM-H2 
gezeigt. Zusätzlich wurde die onkolytische Aktivität von MV-CD30 und VSV-CD30 in vitro 
untersucht. VSV-CD30 tötete beide cHL Tumorzelllinien nach Infektion ab, wohin gegen gesunde 
CD30+ T Lymphozyten vor der Infektion mit CD30-targetieren Viren geschützt waren. VSV-CD30 
replizierte schneller als MV-CD30 und erreichte höhere Maximaltiter. Darüber hinaus gaben 
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infizierte Zellen VSV-CD30 deutlich effizienter in das Zellkulturmedium ab als MV-CD30, so dass 
VSV-CD30 zellfrei aus dem Überstand aufgereinigt werden konnte. 
Für präklinische Studien wurden zwei xenograft Tumormausmodelle von humanem cHL in 
immundefizienten NSG Mäusen etabliert. Zuerst wurde ein lokales Tumormodell etabliert, in dem 
die Tumorzellen in einem subkutanen (s.c.) Tumor wuchsen. Subkutane KM-H2 Tumore wurden 
durch die VSV-CD30 Behandlung in ihrem Wachstum verlangsamt, s.c. L-428 Tumore jedoch nicht. 
Zusätzlich konnte aus s.c. KM-H2 Tumoren replizierendes VSV-CD30 isoliert werden. Das Wachstum 
der s.c. KM-H2 Tumore wurde durch ein Hydrogel aus künstlicher extrazellulärer Matrix („Matrigel“) 
stabilisiert. Demnach wurde ein Tumormausmodell basierend auf KM-H2 Zellen als am besten 
geeignet identifiziert. Basierend darauf wurden die antitumoralen Aktivitäten von MV-CD30 im 
Vergleich zu VSV-CD30 untersucht. Sowohl intratumoral als aus systemisch appliziertes VSV-CD30 
verlangsamte das Tumorwachstum der cHL Tumore über mehrere Wochen, was zu einem 
signifikanten Überlebensvorteil der tumortragenden Mäuse führte. Zusätzlich wurde ein 
disseminiertes Tumormodell etabliert, um das Tumorwachstum einer klinisch relevanten Situation 
besser wiederspiegeln zu können. In diesem Modell reagierten ebenfalls einige Mäuse auf die 
VSV-CD30 Behandlung durch Verlangsamung des Tumorwachstums. Im Unterschied zu cHL waren 
CD30+ anaplastisch-großzellige Lymphom (ALCL) Tumorzelllinien nicht suszeptibel für eine 
Infektion mit VSV-CD30, jedoch für die Infektion mit MV-CD30 in vitro. Diese Beobachtung zeigt, 
dass das onkolytische Potential von VSV-CD30 nicht verallgemeinert werden kann und für jede 
Tumorart einzeln untersucht werden muss. 
Die Charakterisierung von VSV-CD30 in dieser Arbeit liefert die Grundlage, auf der weiterführende 
präklinische Studien durchgeführt werden können für eine Anwendung als Therapeutikum gegen 
cHL.  
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Summary 
Classical Hodgkin lymphoma (cHL) is a hematopoietic malignancy with a characteristic cellular 
composition. The tumor mass is made up of infiltrated lymphocytes and other cells of hematologic 
origin but only very few neoplastic cells that are mainly identified by the diagnostic marker CD30. 
While most patients with early stage cHL can be cured by standard therapy, treatment options for 
relapsed or refractory cHL are still inadequate, although immunotherapy-based approaches for the 
treatment of cHL patients have gained ground in the last decade. As targeting molecule CD30 is in 
focus since it is only minimally expressed on normal cells. Oncolytic viruses (OV) combine the 
selective lysis of tumor cells with the induction of an antitumoral response. Due to the broad 
tropism, strategies to increase tumor specificity were developed. One approach is the retargeting 
of cell entry of viral particles to a receptor of choice through genetic modification of the viral 
envelope. 
This thesis investigates CD30-targeted oncolytic viruses as novel therapeutic concept against cHL 
selectively destroying CD30+ tumor cells. CD30-targeted measles virus (MV-CD30) and vesicular 
stomatitis virus (VSV-CD30) were generated in a previous work and rely on a recently described 
CD30-specific single chain variable fragment (scFv). For VSV-CD30 the VSV glycoprotein G reading 
frame is replaced by those of the CD30-targeted MV glycoproteins. In the current thesis, selectivity 
for the infection of CD30+ cHL cells was demonstrated by infection experiments of two cHL cell lines 
L-428 and KM-H2. In vitro killing capacity of VSV-CD30 vs. MV-CD30 was examined, demonstrating 
that VSV-CD30 induced more rapid and efficient killing of both cHL cell lines. In contrast, CD30+ 
activated healthy T lymphocytes were protected from infection with CD30-targeted viruses. 
Notably, VSV-CD30 yielded much higher titers than MV-CD30 and could be purified out of 
supernatant of infected cells. For preclinical studies, two xenograft tumor mouse models of human 
cHL in immunodeficient NSG mice were designed. First, a local subcutaneously growing cHL mouse 
model was established. Subcutaneous KM-H2 but not L-428 tumors responded to VSV-CD30 
treatment with growth inhibition. In addition, replicating virus could be recovered from tumor 
tissue. After stabilizing tumor growth using “Matrigel” and demonstrating that virus replication is 
not hindered in this extracellular based hydrogel, KM-H2 was identified as a potentially appropriate 
tumor model. Using the established local mouse tumor model, antitumoral activities of both 
MV-CD30 and VSV-CD30 were evaluated.  
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Remarkably, intratumorally, as well as systemically injected VSV-CD30 significantly slowed down 
tumor growth of cHL xenografts resulting in a substantially prolonged survival of tumor-bearing 
mice. Second, a disseminated growing cHL mouse model was established to represent a clinically 
more relevant tumor burden. At least in some mice, VSV-CD30 treatment induced tumor growth 
inhibition, again underlining the CD30 targeting capacity. In contrast to cHL, CD30+ anaplastic large 
cell lymphoma (ALCL) cell lines were not susceptible for the infection with VSV-CD30 but rather for 
the infection with MV-CD30. These findings demonstrate that oncolytic potential of VSV-CD30 
cannot be generalized and has to be separately evaluated for each type of tumor. 
In summary, this study is a proof of concept that VSV-CD30 has oncolytic activity against xenograft 
cHL tumors. It will pave the way for further preclinical investigations to use VSV-CD30 as a novel 
therapeutic agent for the treatment of cHL. 
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1 Introduction 
1.1 Lymphoma 
Lymphomas are part of a heterogeneous group of malignant diseases of the lymphatic system. The 
lymphatic system includes lymph nodes, spleen, thymus, and bone marrow. Therefore, lymphomas 
can affect all those lymphatic areas as well as other organs (extranodal). Lymphomas mainly arise 
from B- or T cells at various stages of development. These lymphocytes change their expression 
profile and underlie lymphomagenesis. The characteristics of the specific lymphomas correlate to 
the cell from which they originated.  
Lymphomas are divided in two main types: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma 
(NHL). HL accounts for about 10% of all lymphomas and is primarily defined histologically by the 
presence of Hodgkin- and Reed-Sternberg (HRS) cells (Pierce and Mehta 2017). Additionally, classical 
HL (cHL) is defined by a constant CD30 expression. NHL represents a rather wide spectrum of illness 
and ranges from indolent to aggressive malignancies (Armitage et al. 2017). Approximately 85-90% 
of NHL are classified as mature B cell neoplasms, whereas the remaining 10-15% are mature T cell 
and natural killer (NK)-cell neoplasms. The relative frequency of specific subtypes of NHL varies 
geographically (Armitage et al. 2017). The diffuse large B-cell lymphoma (DLBCL) is the most common 
subtype of NHL. Besides cHL, also DLCBL and anaplastic large cell lymphoma (ALCL) both as subtypes 
of NHL express a high amount of CD30 (Pierce and Mehta 2017). For DLBCL the usual treatment relies 
on standard chemotherapy regimens and radiotherapy, often in combination with the CD20 
monoclonal antibody rituximab. The addition of rituximab improves the treatment outcome of 
DLBCL. Since CD30 is expressed on a variety of lymphoma subtypes, it was recognized as a potential 
target for therapy.  
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1.1.1 Hodgkin lymphoma 
Classical Hodgkin lymphoma (cHL) was first described by Thomas Hodgkin in 1832 (Hodgkin 1832). 
It is one of the most frequent lymphomas in the Western world which occurs with an incidence of 
3-4 cases per 100.000 persons per year (Küppers 2012). cHL is a malignant disease of the 
hematopoietic system, but can also affect peripheral lymph nodes and extranodel sites such as 
liver, lung, and bone marrow (Küppers 2012). Tumor cells of cHL are composed of mononucleated 
Hodgkin (HL) and bi- or multinucleated Reed-Sternberg (HRS) cells which were first described 
around 1900 by Dorothy Reed and Carl Sternberg (Figure 1.1 A) (Reed 1902; Sternberg 1898). The 
most important immunological marker on malignant HL and HRS cells is CD30 (Figure 1.1 B). CD15 is 
expressed in varying amounts and PAX5 is expressed typically weakly (Mathas et al. 2016). The 
histopathological appearance of cHL is characterized by a unique pattern: Less than 1% of tumor 
cells are embedded in a reactive immune cell infiltrate mainly consisting of T lymphocytes, 
eosinophils, neutrophils, and mast cells (Figure 1.1 C) (Hansen et al. 2016; Pileri et al. 2002). 
Interaction of HRS cells with cells in the microenvironment is based on cytokine secretion and 
interaction with surface receptors. The expression of surface receptors varies a lot, while the 
expression of CD30 is constant. The interaction with rosetting cells is important for survival of HRS 
cells (Schmitz et al. 2009). Most cHL are derived from B cells, but in rare cases they have a T cell 
origin. 
 
Figure 1.1: Hodgkin- and Reed-Sternberg (HRS) cells in their microenvironment 
Morphology and immunhistochemical staining of HRS cells (from cHL of mixed cellularity type) with a bi-nucleated HRS 
cell in the middle of the image surrounded by T lymphocytes (A) Hematoxylin and eosin staining (B) CD30 
immunostaining (C) CD3 immunostaining. Figure is reprinted from (Küppers 2012). 
Four subtypes of cHL are classified by the World Health Organization (WHO) based on histological 
appearance and phenotypes of tumor cells: (1) Nodular sclerosing HL (NSHL), (2) Mixed cellularity 
(MCHL), (3) lymphocyte-rich cHL (LRCHL), and (4) lymphocyte-depleted HL (LDHL).  
Introduction 
 
14 
 
In addition, a non-classical subtype of HL is defined as nodular lymphocyte-predominant HL (NLPHL) 
(Küppers 2012). NSHL is the most frequent subtype in the Western world which mainly occurs as 
large mediastinal tumors in adolescents. It is histologically defined by fibrotic bands which confine 
nodular compartments containing the typical infiltrates of HRS cells surrounded by immune cells. 
MCHL is the second most frequent subtype of cHL which usually occurs in children, elderly people 
or immunocompromised patients. The peripheral lymph nodes are frequently involved with diffuse 
infiltrates of mixed inflammatory background without nodular sclerosing fibrosis. LRCHL is a rare 
subtype of cHL which occurs mostly in adults. It shows a prevalent involvement of cervical lymph 
nodes and the Waldeyer lymphatic tissue. Histologically, LRCHL is characterized by a monomorphic 
pattern, with nodules of mantle zone B cells containing HRS cells. Reactive T lymphocytes rosetting 
HRS cells often express PD-1, which is used as a diagnostic marker. LDHL has become extremely 
rare, since it can now be better distinguished from PAX5-negative ALCL. It occurs more likely in 
immunocompromised patients and HRS cells are rather abundant in the histological pattern (Mathas 
et al. 2016). 
Current treatment options for patients with early stage cHL mainly rely on multi-agent 
chemotherapy (CHOP) and localized radiotherapy (Blank et al. 2017). Patients with chemo-sensitive 
relapsed cHL are treated by autologous hematopoietic stem cell transplantation (HSCT). This 
treatment results in long-term progression-free survival in approximately 50% of patients (Kasamon 
et al. 2017). Recent concepts have started to focus on immunotherapy-based approaches. Based on 
the strong expression on cHL and low expression on normal cells, CD30 is in focus as targeting 
molecule for new therapy options (Scott 2017). Brentuximab vedotin (Adcetris®) is an antibody-drug 
conjugate of a CD30-specific monoclonal antibody coupled with a potent anti-microtubule 
cytotoxin which received marketing authorization in the EU in 2012 (Scott 2017). Used as salvage 
therapy for patients with relapsed or refractory cHL after failed HSCT, it induced a 5-year overall 
survival rate of 41% and thus substantially improved the prospects for cHL patients (Chen et al. 
2016). Another new immunotherapy based option is the use of the PD-1-specific immune checkpoint 
inhibitor nivolumab. It was approved in 2016 for the treatment of patients with relapsed or 
refractory cHL after failed HSCT and brentuximab vedotin treatment (Kasamon et al. 2017). Using α-
PD-1 in these patients, a response rate of 65% was observed.  
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1.1.2 Anaplastic large cell lymphoma 
Anaplastic large cell lymphoma (ALCL) is a subtype of large cell lymphomas and accounts for about 
2-3% of all NHL and 12% of T cell NHL (Pierce and Mehta 2017; Ferreri et al. 2013). The definition is 
based on the frequent proliferation of mainly large lymphoid cells and a constant CD30 expression 
(Stein et al. 2000). Within ALCL four subtypes are classified: (1) Primary systemic anaplastic 
lymphoma kinase (ALK)+ ALCL, (2) Primary systemic ALK- ALCL, (3) Cutaneous ALCL, and (4) Breast 
implant-associated ALCL (Stein et al. 2000; Armitage et al. 2017). All entities usually have a cytotoxic 
T lymphocyte origin and therefore express T lymphocyte associated and cytotoxic markers (Ferreri 
et al. 2013). The expression of the ALK protein is mediated by a translocation between chromosome 
2 and 5 (t(2;5)) involving the ALK gene (Ferreri et al. 2012). ALK+ and ALK- subtypes of ALCL were 
classified as separate disease entities by the WHO in 2016 (Savage et al. 2008). ALK+ALCL 
predominantly occurs in young male patients. It shows a broad morphologic spectrum, where large 
neoplastic cells usually have an abundant cytoplasm and pleomorphic, horseshoe-shaped nuclei. 
It is frequently present at an advanced stage with extranodal involvement (Ferreri et al. 2012). ALK- 
is morphologically not distinguishable from ALK+, but lacks the ALK protein. ALK-ALCL affects older 
patients of both genders. At diagnosis, it is usually present in lymph nodes and less frequently in 
extranodal sites (Ferreri et al. 2013). To distinguish both systemic forms of ALCL from cHL, PAX5 is 
stained which is less present on cHL (Ferreri et al. 2013). Patients with both types of systemic ALCL 
are treated with standard multi-agent chemotherapy (CHOP) (Pierce and Mehta 2017). Patients with 
ALK+ ALCL have a superior treatment outcome of the disease with a 5-year overall survival (OS) of 
70% compared to those with ALK- ALCL which have a 5-year OS of 49% (Savage et al. 2008). Patients 
with relapsed or refractory ALCL are treated with HSCT or alemtuzumab, a monoclonal CD52 
anitbody. Cutaneous ALCL is usually ALK- and has a good prognosis with a 5-year OS of 90% and 
without systemic dissemination in most cases (Savage et al. 2008; Ferreri et al. 2012). 
Due to the constant CD30 expression on all ALCL subtypes, it is in focus for CD30-targeted therapies. 
Brentuximab vedotin is currently tested in clinical trials as substitute of one chemotherapeutic 
drug in the standard chemotherapy regime (Armitage et al. 2017). 
  
Introduction 
 
16 
 
1.2 Oncolytic viruses 
Oncolytic viruses (OVs) are a novel treatment approach mediating selective lysis of tumor cells 
while sparing normal cells. 
During carcinogenesis, innate immune response pathways would lead to an immune reaction 
towards tumor cells. To escape from these immune mechanisms, tumor cells have developed 
aberrant deregulated cell signaling pathways (Berchtold et al. 2013). This includes the activation of 
the Ras signaling pathway and impaired dsRNA-dependent protein (PKR) kinase activity resulting 
in deregulated expression of type I interferons (IFN) α and β (Kirn et al. 2001; Noser et al. 2007; 
Zhang et al. 2010). Due to these deregulated innate immune response pathways many tumor types 
are sensitive towards infection with RNA viruses in particular (Katze et al. 2002). These viruses can 
consequently be considered as treatment option for different types of cancer since they replicate 
in cancer cells but spare normal cells. 
In general, OVs can be divided into two groups: Some viruses have an inherent selectivity for tumor 
cells like parvovirus, reovirus or Newcastle disease virus. Other viruses are adapted and genetically 
modified to be selective for tumor cells like adenovirus, vaccinia virus or herpes simplex virus (HSV) 
(Russell et al. 2012). Compared to other anticancer drugs, OVs have a special mode of killing tumor 
cells. Infected tumor cells are lysed, termed as oncolysis, releasing tumor-associated antigens 
(Breitbach et al. 2016). Thereby OVs promote different mechanisms of antitumor responses. Direct 
oncolysis causes tumor debulking and enables the release of viral particles to infect neighboring 
cells where viral infection amplifies. Furthermore, oncolysis induces a local inflammation with the 
release of cytokines, recruitment of T lymphocytes and other immune cells to the tumor 
microenvironment causing an antitumor immune response. Even when the OV is applied locally 
into the tumor tissue a systemic immune response can be triggered which is crucial for therapy 
efficacy (Guo et al. 2017). Different transgenes have been incorporated into the genome of several 
OVs to further improve their therapeutic efficacy. This includes equipping OVs with genes encoding 
immune activating proteins like the granulocyte-macrophage colony-stimulating factor (GM-CSF). 
By the expression of GM-CSF, recruitment of dendritic cells into the tumor microenvironment is 
improved resulting in an increased presentation to T lymphocytes and enhanced antitumor 
immune responses (Hughes et al. 2014). 
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1.2.1 Oncolytic measles virus 
The measles virus (MV) is a spherical, non-segmented, single-stranded, negative sense RNA (ss(-
)RNA) virus and belongs to the order Mononegavirales, family Paramyxoviridae and genus of 
Morbillivirus. The linear genome consists of 15.894 nucleotides, ordered in six genes that encode 
eight known proteins (Patterson et al. 2000). With the leader and trailer regulatory sequences the 
genome is in the order 3’-(leader)-N-P/C/V-M-F-H-L-(trailer)-5’. 
 
Figure 1.2: Schematic view of a MV virion  
N, L, and P associate together with the RNA genome to the RNP-complex. M clusters to the RNP-complex and forms the 
viral envelope together with the glycoproteins H and F. Figure is reprinted from (Moss and Griffin 2006). 
The viral RNA is tightly associated with the nucleocapsid (N) protein to form a nuclease-resistant 
helical structure where one N protein binds to six nucleotides (Calain and Roux 1993; Aref et al. 
2016) (Figure 1.2). This N decorated RNA forms the functional template for MV RNA synthesis. It 
binds to the RNA-dependent RNA-polymerase (RdRp), which consists of the large polymerase (L) as 
catalytic active subunit and the phosphoprotein (P) as cofactor protein. The N decorated RNA forms 
the ribonucleoprotein (RNP) complex together with L and P as minimal infection unit (Moss and 
Griffin 2006).  
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The MV P gene encodes two additional non-structural gene products, termed C and V proteins 
(Iwasaki et al. 2009). Both are accessory proteins which are virulence factors and involved in the 
pathogenesis of MV for counteracting innate immune defenses (Patterson et al. 2000). The RNP-
complex is linked to the matrix (M) protein via the N protein (Iwasaki et al. 2009). M is associated 
with the inner surface of the plasma membrane which is formed from lipids of the host cell 
membrane. Additionally, M interacts with the cytoplasmic tails of the two MV glycoproteins 
hemagglutinin (H) and fusion protein (F). Both glycoproteins together with the M protein build the 
viral envelope. F mediates membrane fusion of the viral envelope with the host cell membrane after 
the receptor binding of H has induced conformational changes. F is synthesized as an inactive 
precursor form F0. While passing the trans-Golgi network, F0 is proteolytically cleaved by Furin into 
F1 and F2. Both fragments remain linked by a disulfide bond (Mühlebach et al. 2008). 
The tropism of MV is mediated through the receptor binding of H. Wildtype MV enters host cells 
through the receptors SLAM (Signaling Lymphocyte Activation Molecule) (Hsu et al. 2001) or Nectin-
4 (Noyce et al. 2011). SLAM is expressed on activated B- and T-lymphocytes, dendritic cells, and 
macrophages (Tatsuo et al. 2000). By infection of SLAM+ cells, the first systemic spread of MV takes 
place. Nectin-4 is expressed on the baso-lateral side of epithelial cells in the lung (Mühlebach et al. 
2011). Thus, MV particles are released from lung cells to enable infection of other individuals after 
systemic spread. Moreover, Nectin-4 is highly expressed in lung, breast, and ovarian cancer 
(Mühlebach et al. 2011). The viral replication cycle of MV starts with the receptor attachment 
mediated by H. Then, a pH-independent fusion mediated by F of the viral envelope with the host 
cell membrane is initiated. The viral RNP-complex is released into the cytoplasm of the host cell 
where it acts as a template for primary transcription of mRNAs as well as replication into positive-
stranded anti-genomic RNA (Bankamp et al. 2011). The polymerase entry site is located at the 3’-end 
of the genome in the 3’ leader sequence. The genome is organized in six expression cassettes where 
each of them has an initiation sequence and a poly-A termination sequence in the intergenic region 
for transcriptional regulation (Parks et al. 2001). The polymerase stops at the end of a gene and 
reinitiates transcription of the next gene. Thus, single distinct mRNAs from each expression cassette 
are transcribed. With a certain frequency, the polymerase detaches and fails to reinitiate 
transcription of the following downstream genes. This way a transcription gradient with high 
amounts of N protein mRNA and lower amounts of L protein mRNA forms, which directly influences 
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the amount of expressed proteins (Cattaneo et al. 1987; Plumet et al. 2005). Newly transcribed 
mRNAs are capped, polyadenylated and immediately decorated with N proteins. From synthesized 
mRNA templates proteins are translated at the cellular ribosomes. Glycoproteins H and F are 
transported to the host cell membrane via the secretory pathway. Since the RNA is associated with 
N proteins, the transcription stops when sufficient N protein is present in the cell. Then the 
polymerase transcribes a full-length positive sense anti-genomic intermediate. This serves as 
template for the replication of a full-length negative sense genomic RNA (Radecke et al. 1995; 
Bankamp et al. 2011). The genomic RNA forms the RNP complex with the translated N, P and L 
proteins. Via the M protein the RNP complex is connected to the membrane, where H and F are 
expressed. Finally, all assembled components bud from the plasma membrane to complete the 
replication cycle. Dependent on cell type, approximately 30 hours post infection, new viral particles 
are released (Plumet et al. 2005). Due to the expression of H and F on the plasma membrane, MV 
receptor positive neighboring cells are recognized and the formation of multinucleated giant cells, 
termed as syncytia, is induced (Duprex et al. 1999; Aref et al. 2016). Using this characteristic 
cytopathic effect, MV can also spread from cell-to-cell and is not exclusively dependent on viral 
particles. 
For vaccination, live attenuated vaccine strains based on the MV Edmonston (MV-Edm) strain are 
used since 1963 (Hilleman 2001). MV-Edm was isolated from a patient called David Edmonston by 
Enders and Peebles in 1954 (Enders and Peebles 1954). Several MV vaccine strains were attenuated 
by extensive passaging of the isolated virus in cell culture. Moraten and Schwarz strains are mostly 
used for vaccination in the Western world and show a high safety profile (Bankamp et al. 2011). From 
these vaccine strains a variety of recombinant laboratory MV clones have been generated, e.g. 
MVSchw, MVvac2 and MVNSe. Elimination of endonuclease recognition sites generated MVNSe (NSe = NarI-
and-SpeI- eliminated). MVNSe is described to be more fusogenic than the Moraten strain (Devaux et 
al. 2007). MV vaccine strains have an additional tropism for CD46 compared to wildtype MV. The 
additional receptor usage is based on mutations in the H protein obtained during extensive 
passaging for attenuation (Bankamp et al. 2011). CD46 itself is a member of the regulators of 
complement activation and ubiquitously expressed on all human nucleated cells (Dörig et al. 1993). 
On a variety of different malignant diseases CD46 is overexpressed, primarily to evade complement-
mediated lysis (Fishelson et al. 2003). Due to the high expression of CD46 on malignant cells, MV 
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vaccine strains have a high tumor selectivity (Galanis 2010). The formation of syncytia can 
significantly enhance the antitumoral effect of MV since for each infected cell, many neighboring 
cells can fuse to form syncytia followed by apoptotic cell death (Galanis et al. 2001). 
To generate recombinant MVs, a reverse genetic system was developed (Radecke et al. 1995; Takeda 
et al. 2000). Using this system, it was possible to engineer the virus genome and rescue viruses in 
cell culture. MV used as OV in clinical trials is a modified version of the recombinant MV vaccine 
strain MVNSe. By insertion of transgenes, the viral gene expression can be monitored in vivo. 
Recombinant MVs were generated encoding for the sodium iodine symporter (NIS) (Galanis 2010). 
NIS transports and accumulates radioactive 99mTC or  125I in infected cells. It can be detected by 
computed tomography/single-photon emission computed tomography (SPECT-CT) or γ-camera 
imaging (Galanis 2010). Selective infection and lysis of myeloma plasma cells induced by MV-NIS 
was demonstrated. Recently, MV-NIS was tested in a phase I clinical trial by treating two MV-
seronegative patients with relapsing drug-refractory myeloma. Both patients received a systemic 
administration of 1011 TCID50 infectious units of MV-NIS in 100 ml and responded to the therapy. One 
patient showed durable complete remission at all disease sites, while toxicities resolved within the 
first week after therapy (Russell et al. 2014). 
1.2.2 Oncolytic vesicular stomatitis virus 
The vesicular stomatitis virus (VSV) belongs to the order of Mononegavirales being a non-
segmented, single-stranded, negative sense RNA (ss(-)RNA) virus as is MV. In contrast to MV, it is a 
bullet-shaped virus, belonging to the family Rhabdoviridae and genus of Vesiculovirus. The rather 
compact linear genome consists of approximately 11.000 nucleotides, ordered in five genes that 
encode five known proteins (Lichty et al. 2004). 
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Figure 1.3: Schematic view of a VSV virion 
The genome encodes the five gene products: N (nucleoprotein), P (phosphoprotein), M (matrix protein), G (glycoprotein) 
and L (large polymerase). N, L, and P associate together with the RNA genome to the RNP-complex. M clusters to the RNP-
complex and builds together with the glycoprotein G the viral envelope. Figure is reprinted from (Lichty et al. 2004) 
The RNA genome is tightly decorated with the nucleoprotein (N) (Figure 1.3). The RdRp, which is 
highly homologous within the order of Mononegavirales, consists of the large polymerase (L) as 
catalytic active subunit and its co-factor the phosphoprotein (P) (Hastie and Grdzelishvili 2012). The 
N decorated RNA genome is associated with the RdRp to an RNP complex. The RNP complex in turn 
is connected with the matrix (M) protein, which is located at the lipid bilayer on the cytosolic site. 
The M protein has multiple functions in addition to the role during assembly and budding of new 
viral particles (Barr et al. 2002). First, it partially regulates the transcription of VSV genes by RdRp 
(Lichty et al. 2004). Second, it prevents that VSV is recognized by cellular antiviral programs. More 
precisely, the cellular transcription programs are interrupted and the cellular mRNA export from 
the nucleus is blocked (Petersen et al. 2000; Ahmed et al. 2003; Lichty et al. 2004). Hence antiviral 
genes like IFN-β are blocked and VSV can replicate unabated (Ahmed et al. 2003). Third, the M 
protein is responsible for cell rounding as cytopathic effect leading to apoptotic cell death of 
susceptible host cells (Lichty et al. 2004). 
Unlike MV, VSV has only one glycoprotein (G) which mediates receptor binding and fusion of viral 
and cellular membranes (Sun et al. 2010). G has a trimeric structure and binds to the low density 
lipoprotein (LDL) receptor, which is ubiquitously expressed (Finkelshtein et al. 2013). Therefore, VSV 
has a very broad tropism and can infect virtually all animal cells (Lichty et al. 2004). Other than MV, 
VSV enters the cell via pH-dependent clathrin-mediated endocytosis after receptor binding (Sun et 
al. 2005).  
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The virus is engulfed, then trafficked into endosomal vesicles and released during subsequent 
acidification of the endosome (White et al. 1981; Sun et al. 2010). The pH drop triggers a 
conformational change in the G protein which catalyzes the fusion of viral envelope and endosomal 
membrane (Sun et al. 2010). This way the RNP complex is released into the cytoplasm and 
replication is initiated. Similar to the replication cycle described for MV, the polymerase complex 
for transcription of the genome is delivered with the RNP complex. The single polymerase entry 
site is located at the 3’-end of the genome, which makes the transcription obligatory sequential 
(Ball and White 1976; Emerson 1982; Bishnoi et al. 2018). Between the five expression cassettes, cis-
elements serve as start/stop sequences to regulate transcription (Barr et al. 2002). First, individual 
mRNAs for each viral gene are transcribed. A transcription gradient due to the re-initiation fail of 
the polymerase is present as well, which leads to lower amounts of proteins expressed from 
downstream genes (Iverson and Rose 1981; Hastie and Grdzelishvili 2012). Viral mRNAs are 
translated into proteins by the host ribosomes. At later stages, the polymerase complex switches 
from transcription to replication. Here, for replication of the negative-sense RNA genome, a positive-
sense anti-genome as intermediate is synthesized by the polymerase as well. The assembly of the 
first batch of progeny virions is coincidental to the secondary viral genome transcription (2-3 hours 
post infection) (Bishnoi et al. 2018). Finally, all assembled components are packaged into new 
progeny VSV virions.  
Using reverse genetic tools recombinant VSV has been generated de novo in cell culture (Schnell 
et al. 1994; Bishnoi et al. 2018). This was the prerequisite to modify VSV and develop promising 
candidates to use as oncolytic virus. VSV is non-pathogenic to humans, has a well-studied biology 
and a genome that is easily manipulable, has a rapid replication cycle and can be produced in high 
viral titers. Furthermore, VSV has high tumor selectivity due to its high sensitivity towards IFN. 
However, the main issue of VSV is its inherent neurotoxicity. Neurotropism is primarily mediated 
by the G protein and partly by the M protein (Bishnoi et al. 2018). VSV application in different in vivo 
models leads to an invasion of the central nervous system following severe neurological diseases 
(Johnson et al. 2007; Muik et al. 2012; Shinozaki et al. 2005). Several modifications of VSV were done 
to increase the safety, resulting in the generation of different recombinant VSV bearing certain 
mutations in a viral gene or expressing a foreign antigen (Lichty et al. 2004). One approach to 
increase oncoselectivity is the use of VSV-M∆51. The methionine at position 51 of the M protein is 
Introduction 
 
23 
 
mutated, thus unblocking the nucleocytoplasmic transport of host mRNA. This way, IFN from non-
cancer cells is produced protecting them from infection with VSV (Stojdl et al. 2003). Another 
approach to attenuate VSV replication in healthly tissue is the development of a recombinant VSV 
encoding IFN-β (Obuchi et al. 2003). Preclinical studies showing off-target free toxicity in malignant 
cells are promising and therefore VSV-IFNβ is investigated in ongoing clinical trials 
(ClinicalTrials.gov Identifier: NCT03017820, NCT02923466). To neutralize neurotoxicity of VSV, one 
approach is the exchange of VSV-G glycoprotein as key determinant of VSV neurovirulence. It was 
shown that by exchanging the glycoprotein of VSV with the glycoprotein of lymphocytic 
choriomeningitis virus (LCMV) in different in vivo models, neurotoxicity can be eliminated (Muik et 
al. 2011; Muik et al. 2014). 
 
1.3 Receptor targeting of oncolytic RNA viruses  
Viral tropism is determined through the susceptibility and permissiveness of a host cell for an 
infection. This means, that the virus binds to a surface receptor through its viral glycoproteins for 
cell entry on a susceptible target cell. Post entry, the permissive host cell provides transcription 
factors and nutrients to allow viral replication. To target viruses to certain cell types, there are two 
main strategies: First, the cell entry of viral particles can be targeted to a receptor of choice through 
genetic modification of the viral envelope. Second, the viral replication in healthy tissue can be 
inhibited on post-entry level by silencing viral mRNA translation. This can be achieved i.a. by the 
insertion of microRNA target sites into the genome of MV (Leber et al. 2018; Edge et al. 2008). This 
thesis is focusing on retargeting the viral cell entry of MV and VSV to a receptor of choice by 
modifications of the viral envelop. 
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1.3.1 Receptor targeting of measles virus 
Targeting of MV to a receptor of choice is well characterized and established. First of all, a specific 
binding ligand needs to be fused to MV-H, mediating receptor attachment. Since the fusion of a 
large antibody with tetrameric structure and disulfide bonds is not possible, engineered binding 
domains are used. In the beginning of targeting approaches, a ligand (Schneider et al. 2000), a 
peptide (Hallak et al. 2005) or a single chain variable fragment (scFv) (Hammond et al. 2001) was 
fused to the extracellular part of MV-H protein to achieve an extended tropism. For complete 
retargeting of MV, the inherent binding sites for the natural receptors need to be erased. Thus, MV-H 
is blinded by the insertion of four specific point mutations in the receptor binding sites for CD46, 
SLAM and Nectin-4 (abbreviated as Hmut). Subsequently a targeting domain with a specificity of 
choice is fused to Hmut (Nakamura et al. 2005). For this approach frequently used targeting domains 
are scFv. They contain the antigen-binding variable regions of the heavy and light chains of an 
antibody and retain complete antigen specificity. These modifications of Hmut leads to MV particles 
that do no longer bind to natural MV receptors, but with high affinity to the receptor of choice which 
is targeted by the scFv. Utilizing this retargeting concept, a series of MV were generated each using 
a particular type of tumor surface marker as entry receptor (Aref et al. 2016). One example is an 
oncolytic MV specifically retargeted to CD133+ tumor-initiating cells, which are described for various 
tumor entities, including hepatocellular carcinoma and glioblastoma. MV-CD133 selectively 
eliminated CD133+ tumor cells and was more effective in prolonging survival of tumor bearing mice 
compared to MVNSe. (Bach et al. 2013) 
Besides scFv, artificial binding domains based on designed ankyrin repeat proteins (DARPins) are 
used as targeting domains with antibody-like specificity for retargeting MV. Using DARPins, 
oncolytic MV retargeted to three different tumors markers (Epidermal growth factor receptor (EGFR), 
human epidermal growth factor 2 (Her2/neu) and epithelial cell adhesion molecule (EpCAM)) were 
generated and shown to eliminate tumor xenografts. To circumvent therapy resistance based on 
down regulation of a tumor marker, a bispecific targeting of MV using DARPins was demonstrated 
as well. (Friedrich et al. 2013) 
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1.3.2 Receptor targeting of vesicular stomatitis virus 
Until now, complete retargeting of VSV using the inherent glycoprotein VSV-G was not possible. 
However, VSV tolerates the incorporation of glycoproteins from other virus families very well. In 
2006, a recombinant, replication competent VSV that preferentially infects Her2/neu-positive breast 
cancer cells, was generated. This was achieved by generating a VSV-Sindbis pseudotype. The native 
VSV-G glycoprotein was deleted and instead a chimeric Sindbis glycoprotein which included a scFv 
specific for Her2/neu was inserted. However, after several cycles of passaging on a target cell line, 
viral replication was reduced and viral yield was poor (Gao et al. 2006). A different approach to 
retarget VSV to tumor vasculature associated integrins using VSV-G itself was investigated in 2013. 
A replication competent VSV displaying different tumor-targeting ligands on the surface of VSV-G 
was generated. The feasibility of the approach for the insertion of two integrin-binding peptides 
was demonstrated. First a 9-amino-acid cyclic RGD peptide, second a 49-amino-acid echistatin 
domain was fused. Both ligand-displaying VSV replicated as efficiently as parental VSV and showed 
specificity to bind to targeted integrins. Furthermore, the authors investigated the insertion of scFv 
specific for EGFR or Her2/neu. However, VSV displaying scFv grew to lower maximum titers than 
unmodified VSV and the EGFR-scFv was partially cleaved from the G-protein (Ammayappan et al. 
2013). In 2012, Ayala-Breton et al. for the first time generated a fully retargeted, but replication 
deficient VSV-MV pseudotype. VSV-G was deleted and a chimeric MV-H fused to a scFv specific for 
EGFR, FR or PSMA together with MV-F were inserted. Viral particles were produced, but viral titers 
were moderate. Specificity of all viruses for receptor positive tumor cells was shown on transgenic 
cell lines in vitro as well as in human xenograft tumors in vivo (Ayala-Breton et al. 2012). A 
replication competent VSV-MV pseudotype was investigated in 2013 and 2014. Here, VSV-G was 
deleted and unmodified MV glycoproteins were inserted. The generated VSV-MV chimera infected 
MV-receptor positive tumor cells and formed syncytia in vitro. The authors claimed that VSV-MV 
harnessed the safety of oncolytic MV and spread with VSV-like kinetics. In a myeloma xenograft 
model VSV-MV showed higher oncolytic activity compared to MV or VSV-M∆51. Due to the deletion 
of VSV-G it proved not to be neurotoxic. Generating this kind of VSV-MV chimera was the basis for 
a fully retargeted replication competent VSV (Ayala-Breton et al. 2013; Ayala-Breton et al. 2014). 
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1.4 Objectives 
Aim of this study was the characterization of two CD30-targeted oncolytic viruses with respect to 
their antitumoral activity against cHL and ALCL cell lines. Until now, oncolytic virotherapy has not 
been considered for the treatment of cHL. Compared to other tumor entities, the frequency of tumor 
cells in the affected tissue of cHL is low, which makes the use of conventional oncolytic viruses 
challenging. Additional layers of tumor cell targeting may be beneficial to establish an effective 
virotherapy strategy for cHL. Since tumor cells of cHL constantly express CD30, this surface 
molecule is in focus for new therapy approaches of cHL. For this purpose both, a CD30-targeted MV 
and for the first time a completely retargeted VSV-MV chimera had been generated (Hanauer 2015). 
CD30-targeted viruses are designed to induce oncolysis in CD30+ tumor cells leading to apoptotic 
cell death and tumor shrinkage. Using a CD30-targeted VSV as oncolytic agent is thought to be 
beneficial compared to MV due to its faster replication kinetics. 
New virus stocks had to be produced and characterized for their potential application in vivo. This 
involved the analysis of the particle assembly as well as their ability to induce cell killing of two 
different cHL cell lines in vitro. Next, a suitable cHL xenograft tumor mouse model had to be 
established for the evaluation of CD30-targeted viruses in vivo. For this purpose, two different cHL 
cell lines were investigated in regard to formation of a s.c. tumor and their susceptibility for the 
infection with CD30-targeted viruses. Using the established s.c. tumor mouse model, the oncolytic 
activities of both MV-CD30 and VSV-CD30 had to be evaluated using different virus application 
routes. In addition, a multifocal growing cHL tumor mouse model reflecting the clinically relevant 
tumor burden had to be established. First, a cHL cell line allowing tumor development observation 
in vivo had to be generated and analyzed for its susceptibility to VSV-CD30. Second, the established 
multifocal tumor model had to be used to evaluate the oncolytic activity of VSV-CD30 as well. 
Finally, the susceptibility of different CD30+ ALCL cell lines had to be investigated in vitro. 
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2 Material and methods 
2.1 Material 
2.1.1 Instruments 
Table 1: Instruments 
Name  Manufacturer 
Centrifuge: Multifuge X3R  Heraeus, Thermo Scientific  
Cryo freezing container Nalgene 
Cryostat: CM1900 Leica 
Digital caliper PMS 
Flowcytometer: MACSQuant Analyzer 10 Miltenyi Biotec  
Fluorescence microscope: Axio Observer X1, ApoTome 
optical sectioning unit 
Carl Zeiss, Jena 
Fluorescence microscope: Axiovert 200, AxioCam  Carl Zeiss, Jena  
Humidified CO2-incubator: BBD6220  Heraeus, Thermo Scientific  
In vivo Imaging System: IVIS Spectrum Perkin Elmer 
Laminar Flow Cabinet Class II  The Baker Company  
Light microscope: Axiovert 25  Carl Zeiss, Jena  
Microplate luminometer: Microlumat Plus LB 96V Berthold Technologies  
Microcentrifuge: Biofuge fresco  Heraeus, Thermo Scientific  
Micropipettes (10 μl, 100 μl, 1000 μl)  Brand/Eppendorf  
Multichannel pipettes: Eppendorf Research plus Eppendorf  
Pipetting assistance: Accu-jet  Brand  
Semi-dry blotter: Transfer Cell SD  Bio-Rad  
Small animal anesthetic device: indulab-vet HME-Highland Medical Equipment 
Western Blot film processor: Curix 60 Agfa 
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2.1.2 Consumables 
Table 2: Consumables 
Name  Vendor 
1.5 ml reaction tube Eppendorf 
BD Vacutainer Safety-Lok Blood Collection Set Becton Dickinson 
BD Vacutainer® CPT™ Mononuclear Cell Preparation Tube Becton Dickinson 
Bottle Top Filter 500 ml, 0.45 μm SFCE, Rapid-Flow  Thermo Fisher Scientific 
Canulas: Sterican (various types)  Braun  
Cell culture dish (15 cm) TPP  
Cell culture microplate, 96 well, µCLEAR®, black Greiner Bio-One 
Cell scraper TPP 
Cell strainer (70 μm) BD Biosciences  
Cryovial (2 ml)  Greiner Bio-One  
FACS tubes (1.4 ml) Micronic 
Falcons, CellStar Tubes (15 ml, 50 ml) Greiner Bio-One 
High performance chemiluminescent films  GE Healthcare  
Nitro cellulose membrane, Hybond ECL GE-Healthcare  
Pipette tips, filtered (10 μl, 100 μl, 300 μl, 1000 μl)  Nerbe Plus, Biotix, Biozym 
Serological pipettes (2 ml, 5 ml, 10 ml, 25 ml)  Greiner Bio-One  
Size exclusion filter, Amicon Ultra-15, 100 kDa Merck 
Slides, Superfrost Plus  Menzel  
Syringe filters, Minisart PTFE (0.45 μm, 0.2 μm)  Satorius  
Syringe: Omnifix® (1 ml, 5 ml, 10 ml, 20 ml)  Braun  
Syringe: BD MicroFine, 1 ml, U100, 29G Insulin BD Biosciences 
Tissue culture flask (T25, T75, T175) Greiner Bio-One  
Tissue culture plates (96-, 48-, 24-, 12-, 6-well) Nunc, Thermo Fisher Scientific  
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2.1.3 Reagents  
Table 3: Reagents 
Reagent  Vendor 
Acrylamide (Rotiphorese® Gel 30) Carl Roth 
Ammonium persulfate (APS) Sigma-Aldrich 
Bovine Serum Albumin (BSA) Sigma-Aldrich 
CD30-Fc protein (Friedel et al. 2015) 
Corning® Matrigel® Basement Membrane Mix Thermo Fisher Scientific 
Dimethylsulfoxide (DMSO), 99.9% p.a. Sigma-Aldrich 
Dithiothreitol (DTT) Sigma-Aldrich 
Donkey serum  Chemicon  
Dulbecco’s Modified Eagle Medium (DMEM)  Lonza, Biowest 
FcR blocking reagent, murine Miltenyi Biotech 
Fetal calf serum (FCS)  Biochrome  
Fluoroshield™ DAPI (4 ,6-diamidino-2-phenylindole) Sigma-Aldrich  
Formaldehyde, 37% p.a. (ROTIPURAN®) Carl Roth 
Glycerol Sigma-Aldrich 
H2O (tissue culture grade)  Sigma-Aldrich 
HEPES solution Sigma-Aldrich 
Interleukin-2 (IL-2), human Miltenyi Biotech 
Isoflurane CP CP-Pharma 
Isopropanol VWR Chemicals 
L-glutamine  Sigma-Aldrich 
Methanol VWR Chemicals 
N,N,N’,N’ Tetramethylenediamine (TEMED) Carl Roth  
OptiMEM® Gibco, Life Technologies 
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PageRuler™ Plus Prestained Protein Ladder Thermo Fisher Scientific 
PBS (w/o Mg2+/Ca2+)  Lonza  
Penicillin/Streptomycin (PenStrep) Paul-Ehrlich-Institut 
Pierce™ ECL Western Blotting Substrate Thermo Fisher Scientific 
Powdered milk, low fat  Carl Roth  
Puromycin  Gibco, Life technologies 
Roti®-Histofix 4% Carl Roth 
RPMI 1640 medium  Biowest  
Sodium dodecyl sulfate (SDS) Carl Roth 
Sucrose Sigma-Aldrich  
Tissue-Tek® O.C.T. Compound Sakura® Finetek 
Triton X-100 Sigma-Aldrich  
Trypan blue  Sigma-Aldrich  
Trypsin 2.5% Paul-Ehrlich-Institut  
Tris Paul-Ehrlich-Institut 
Tween-20 Sigma-Aldrich  
Urea, p.a. Sigma-Aldrich 
VP-SFM (virus production serum free medium) Life technologies 
Xenolight D-Luciferin Perkin Elmer 
 
2.1.4 Commercially available kits 
Table 4: Commercially available kits 
Name  Vendor 
eBioscienceTM Fixable Viablity Dye eFluorTM 450 Thermo Fisher Scientific 
RealTime-Glo™ MT Cell Viability Assay Promega 
LIVE/DEAD Fixable Violet Dead Cell Stain Kit Molecular Probes 
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2.1.5 Software 
Table 5: Software 
Name Vendor 
Axio Vision 4.8 Carl Zeiss, Jena 
Citavi 6.0 Swiss Academic Software  
FCS-Express 6.0 De Novo Software  
GraphPad Prism 7.0 Graph Pad Software 
Living Image 4.2 Perkin Elmer 
Microsoft Office 2010 Microsoft 
WinGlow 1.25 Berthold Technologies 
 
2.1.6 Media and Buffers 
Table 6: Media and Buffers 
Name Composition 
Ammoniumchloride 0.86% ammoniumchloride  
in H2O 
Blocking buffer (WB)  5% powdered milk 
in TBS-T 
FACS fixation buffer  1% formaldehyde 
in PBS w/o Mg2+/Ca2+ 
FACS wash buffer  2% FCS 
0.1% NaN3 
in PBS w/o Mg2+/Ca2+ 
Freezing medium 10% DMSO 
90% FCS 
PBS/EDTA 2 mM EDTA 
in PBS w/o Mg2+/Ca2+ 
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SDS loading buffer (4x) 
 
250 mM Tris/HCL (pH 6.8) 
4% SDS 
20% glycerol 
20 mg bromophenol blue 
10% β-Mercaptoethanol 
in H2O 
SDS running buffer 25 mM Tris  
192 mM glycine 
1% SDS 
in H2O 
Sucrose 30% Sucrose 
in PBS w/o Mg2+/Ca2+ 
T cell medium 10% FCS 
2 mM L-glutamine 
25 mM HEPES 
0.4% Penicillin/Streptomycin 
in RPMI 1640 
TBS buffer  
 
50 mM Tris  
150 mM NaCl  
in H2O  
TBS-T I buffer 
 
0.1% Tween-20 
in TBS buffer 
TBS-T II buffer 0.2% Triton X-100 
in TBS buffer 
Transfer buffer (WB) 
 
48 mM Tris  
39 mM glycine  
20% v/v methanol  
in H2O  
Trypsin working solution 2 mM EDTA 
0.25% Trypsin-Melnick 
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in PBS w/o Mg2+/Ca2+ 
Urea-denaturation buffer (2x) 
 
200 mM Tris-HCl  
8 M Urea  
5% SDS  
100 mM EDTA 
0.03% bromophenol blue 
1.5% (w/v) DTT 
in H2O 
 
2.1.7 Antibodies 
Table 7: FACS antibodies 
Antibody  Clone Vendor 
mouse α-human CD3-Pacific Blue UCHT1 BD Pharmingen 
mouse α-human CD25-APC-Cy7 BC96 BioLegend 
mouse α-human CD30-PE Ki-2 Miltenyi Biotec  
mouse α-human CD46-FITC MEM-258 Biolegend 
mouse α-human CD150 (SLAM)-PE A12 (7D4) Biolegend 
 
Table 8: Western Blot (WB) antibodies 
Antibody Dilution Vendor 
goat α-rabbit-HRP 1:2.000 DAKO Cytomation 
rabbit α-MV-F (1034), polyclonal 1:4.000 Abcam 
rabbit α-MV-H (606), polyclonal 1:1.000 Abcam 
rabbit α-MV Hcyt purified IgG VSEP103081, 
rabbit 1141 ZDE 10143 
1:20.000 Eurogentec 
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Table 9: T cell activation antibodies 
Antibody  Clone Vendor 
mouse α-human CD3 OKT3 Miltenyi Biotec  
mouse α-human CD28 15E8 Miltenyi Biotec 
 
Table 10: Immunofluorescence (IF) antibodies 
Antibody Dilution Vendor 
donkey α-rabbit IgG Cy2 1:200 Jackson ImmunoResearch 
donkey α-rat IgG Alexa-Fluor647 1:200 Jackson ImmunoResearch 
rabbit α-GFP, polyclonal IgG serum 1:200 Invitrogen 
rat α-mouse CD31, clone: SZ31 1:10 Dianova 
 
2.1.8 Viruses 
Table 11: Viruses 
Name  Description  
MV Parental MVNSe, recombinant clone of MV laboratory strain 
derived from Edmondston B vaccine strain, encodes for eGFP(N), 
(Radecke et al. 1995)  
MV-CD30 Transgenic MVNSe encodes for HRS3opt2#2-scFv (Hmut-CD30scFv) 
and eGFP(N), (Hanauer 2015) 
VSV-MV Parental VSV-MV, based on VSV Indiana serotype, encodes for 
MV glycoproteins F and H as well as eGFP, (Ayala-Breton et al. 
2014) 
VSV-CD30 Transgenic VSV-MV, encodes for MV glycoproteins F and 
Hmut-CD30-scFv as well as eGFP, (Hanauer 2015) 
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2.1.9 Cell lines  
Table 12: Cell lines 
Name  Description  Origin  
HT1080-CD30  Human fibrosarcoma cell line genetically 
engineered to express human CD30  
(Friedel et al. 2015) 
Karpas299 Human anaplastic large cell lymphoma 
(ALCL) cell line (ALK+) 
German Collection of 
Microorganisms and Cell 
Cultures, Braunschweig 
KM-H2 Human classical Hodgkin lymphoma (HL) 
cell line (Subtype: mixed cellularity) 
German Collection of 
Microorganisms and Cell 
Cultures, Braunschweig 
KM-H2-luc Human classical Hodgkin lymphoma (HL) 
cell line genetically engineered to 
express firefly luciferase 
This thesis  
L-428 Human classical Hodgkin lymphoma cell 
line (Subtype: nodular sclerosis) 
German Collection of 
Microorganisms and Cell 
Cultures, Braunschweig 
MAC-1 Human anaplastic large cell lymphoma 
(ALCL) cell line (ALK-, cutaneous T cell 
ALCL) 
(Kadin et al. 1994) 
SUDHL-1 Human anaplastic large cell lymphoma 
(ALCL) cell line (ALK+) 
German Collection of 
Microorganisms and Cell 
Cultures, Braunschweig 
Vero-αHis Kidney epithelial cells from 
Cercopithecus aethiops genetically 
engineered to express a αHis6-tag-scFv 
displayed on the PDGFR TM domain  
(Nakamura et al. 2005) 
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2.2 Protein biochemical methods 
2.2.1 SDS-PAGE 
SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) is a method to 
electrophoretically separate SDS-decorated proteins according to their molecular weight using a 
polyacrylamide gel. Protein samples (here: virus stocks) were mixed with 2x urea-denaturation 
butter or 4x SDS loading buffer and incubated for 10 min at 95°C for denaturation. Samples were 
loaded to 10% SDS polyacrylamide gels and separated using a gel electrophoresis chamber filled 
with 1x SDS running buffer. The polyacrylamide gels used for separation were prepared as described 
in Table 13. 
Table 13: Composition of polyacrylamide stacking and separation gel  
Components Stacking gel (5%) Separation gel (10%) 
30% acrylamide 
(Rotiphorese® Gel 30) 
1.65 ml 6.6 ml 
1 M Tris, pH 8.8 - 7.8 ml 
1 M Tris, pH 6.8 1.25 ml - 
50% glycerol - 1.64 ml 
10% SDS 100 µl 220 µl 
H2O 7.00 ml 3.70 ml 
TEMED 26 µl 26 µl 
20% APS 52 µl 52 µl 
 
Electrophoretic separation was performed at 100 V until the running front reached the resolving 
gel, then proteins were further separated with 120 V until the desired marker proteins reached the 
end of the resolving gel. As size standard for comparison of the applied samples, the PageRuler™ 
Plus Prestained Protein Ladder (Thermo Fisher Scientific) was used. 
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2.2.2 Western Blot analysis  
After electrophoretic separation (2.2.1), proteins were transferred onto a nitrocellulose membrane 
and used there for immunodetection by Western Blot. Proteins were transferred electrically using 
a semi-dry blotter. Filter (Whatman) paper, nitrocellulose membrane and the polyacrylamide gel 
were pre incubated in Transfer buffer. Next, all components were stacked carefully onto the 
electrode of the blotter machine. Proteins were transferred at 0.18 A for 90 min. Afterwards, proteins 
on the membrane were blocked with TBS-T containing 5% milk powder for 30 min. Subsequently, 
the membranes were incubated with primary antibodies diluted in blocking buffer and incubated 
at 4°C over night. Antibody solution was removed following the incubation time and membranes 
were washed three times with TBS-T. Horseradish peroxidase (HRP)-conjugated secondary 
antibodies were diluted in blocking solution and used for membrane incubation at room 
temperature for 30 min. Antibody solution was removed and membranes were washed three times 
with TBS-T. Protein signals were detected using the Pierce™ ECL Western Blotting Substrate (Thermo 
Fisher Scientific). 
 
2.3 Cell culture methods 
2.3.1 Cultivation of eukaryotic cell lines 
Eukaryotic cell lines were cultivated under standard cultivation conditions at 37°C in an atmosphere 
containing 5% CO2 and 95% humidity. Cells were cultured in DMEM or RPMI media supplemented 
with 10% heat-inactivated FCS and 2 mM L-glutamine (10% FCS, 1% L-glutamine) and cultured in T175, 
T75 or T25 cell culture flasks. Depending on cell growth, cells were split twice a week in different 
ratios to maintain confluence of 80-90%. Medium from cells was removed and cells were washed 
with PBS. To detach adherent cells from the cell culture flask, PBS-Trypsin-EDTA was added to 
remaining cells and incubated at 37°C until cells detached. By resuspending the cells in fresh media, 
the detachment process was stopped. A part of the cell suspension was then discarded or used for 
subsequent experiments. The remaining cells were supplied with fresh media and distributed to 
new cell culture flasks. All cell lines were checked for contaminations with mycoplasma by PCR on 
a regular basis. 
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2.3.2 Freezing and thawing of cells 
To freeze cells, the cell culture was expanded at a minimum of four T175 cell culture flasks. At a 
confluence of 80%, cells were detached, pooled and centrifuged for 5 min at 300xg and 4°C. The 
remaining cell pellet was then resuspended in ice cold freezing medium, aliquoted into cryovials 
(1 ml/vial) and frozen at -80°C using a Mr. Frosty Freezing Container (Nalgene) filled with 
Isopropanol. On the next day, cells were transferred to the gas phase of a liquid nitrogen tank and 
stored at -155°C.  
For thawing cells, a cryovial containing cells was thawed at room temperature or in the water bath 
at 37°C. Immediately after thawing, cell suspension was transferred to a reaction tube filled with 
pre-warmed medium and centrifuged for 5 min at 300xg and 4°C. The cell pellet was then 
resuspended in appropriate pre-warmed culture medium (10% FCS, 1% L-glutamine) and cells were 
seeded in a T75 cell culture flask. On the next day, cell culture medium was exchanged. 
2.3.3 Isolation and activation of human peripheral blood mononuclear cells  
Primary human peripheral blood mononuclear cells (PBMC) were isolated from fresh healthy human 
donor blood by density centrifugation. To do so, Vacutainer® CPT™ Mononuclear Cell Preparation 
Tubes (Becton Dickinson) were used according to the manufacturer’s protocol. Following density 
centrifugation, erythrocytes and granulocytes were pelleted. The layer containing the mononuclear 
lymphocytes, monocytes and macrophages was aspirated from the interphase. Obtained PBMC were 
washed twice with PBS. Remaining erythrocytes were lysed for 10 min at 37°C using 0.86% 
ammonium chloride. After two additional washing steps with PBS, cells were counted and 
resuspended in T cell medium supplemented with 100 U/ml interleukin-2 (IL-2) (Miltenyi Biotec). 
For activation, PBMC were seeded in plates pre-coated with 1 µg/ml α-human CD3 antibody (Miltenyi 
Biotec) and 3 µg/ml α-human CD28 antibody (Miltenyi Biotec) and cultured for 72 h. After infection, 
cells were cultured in T cell medium supplemented only with IL-2. 
2.3.4 Generation of stably transgenic cell lines 
Cell stably expressing an introduced transgene were generated by transduction with a lentiviral 
vector (LV) encoding for the transgene and a puromycin resistance gene.  
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KM-H2-luc cells were generated by transduction with a VSV-G-HIV1-Puro-Luc LV transferring the 
luciferase transgene and a puromycin resistance gene. For transduction of parental KM-H2 cells 
unconcentrated supernatant of LV producer cells was used. To do so, 1 x 105 cells were seeded in a 
48-well plate and transduced with different volumes of vector stock (10-100 µl). After 24 h of 
transduction, 1 ml of RPMI (10% FCS, 1% L-glutamine) was added to the cells. Selection of transgene 
expressing cells was achieved by supplementing the cell culture medium with 10 µg/ml puromycin 
three days after transduction. KM-H2-luc cells were selected for two weeks and afterwards verified 
for luciferase expression using the luciferase assay system (Promega) according to the 
manufacturer’s protocol. KM-H2-luc cells showing luciferase activity were expanded and frozen. 
2.3.5 Surface staining and flow cytometry analysis 
For staining, cell suspension was transferred to micronic tubes. Next, cells were washed twice with 
FACS washing buffer and centrifuged for 3 min at 300xg and 4°C. Cells were incubated with an 
appropriate dilution of antibody in FACS washing buffer and incubated for 30 min at 4°C. To remove 
unbound antibody, cells were washed again twice with FACS washing buffer and were then fixed 
with 200 µl FACS Fix buffer. Flow cytometry analysis was performed at the MACSQuant Analyzer 10 
(Miltenyi Biotec) and data were analyzed using FCS express V4 and V6 (De Novo Software). 
 
2.4 Virological methods  
2.4.1 Preparation of cell-associated MV stocks 
1.5 x 107 Vero-αHis cells were seeded in 15 cm cell culture dishes in DMEM (10% FCS, 1% L-glutamine) 
and infected with an MOI of 0.03. Infected cells were cultivated for 48 h at 37°C until at least 50% 
of the area was covered by syncytia. To harvest cell-associated MV, supernatant of infected cells 
was discarded and 1 ml of OptiMEM was added per cell culture dish. Adherent cells were detached 
using a cell scraper and cell suspension from several dishes was pooled in a 15 ml falcon tube. After 
snap-freezing the tube in liquid nitrogen, cell suspension was thawed at 37°C. Cell debris was 
removed by centrifugation for 5 min at 750xg and 4°C. Virus-containing supernatant was aliquoted 
into cryovials and frozen at -80°C for storage. 
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2.4.2 Preparation of supernatant VSV stocks 
1.5 x 107 Vero-αHis cells were seeded in T175 cell culture flasks in VP-SFM (1% L-glutamine) and 
infected with an MOI of 0.01. Infected cells were cultured for 24 h at 37°C, followed by incubation 
for 24 h at 32°C until at least 50% of the area was covered by syncytia. Supernatant (SN) of infected 
cells was collected and pooled. Cell debris in the supernatant were first removed via centrifugation 
for 5 min at 3000xg and second by filtration through a 0.45 µm bottle top filter. Concentration of 
virus containing supernatant was performed using an Amicon 100K size exclusion filter (Merck). 
Volume was concentrated to 500 µl per size exclusion filter after centrifugation at 3000xg for 1.5 h. 
After concentration, virus stocks were sterile filtrated through a 0.22 µm filter. Virus-containing 
supernatant was aliquoted into cryovials and frozen at -80°C for storage.  
2.4.3 Determination of the TCID50/ml 
Viral titers of MV or VSV-MV were calculated by the 50% Tissue Culture Infective Dose (TCID50/ml). 
First, 1 x 104 permissive Vero-αHis cells were seeded in a 96-well-plate. The viral suspension of 
unknown titer was diluted in two individual dilution series ranging from 10-1 to 10-8 in DMEM. 
Vero-αHis cells were infected with 30 µl of each dilution step in eight replicas and cultivated at 
standard cultivation conditions. Depending on the viral kinetic, cells were analyzed for syncytia 
formation 48-96 h post titration via fluorescence microscopy.  
Based on syncytia-positive counted wells, the viral titer was calculated using the equation of 
Spearman and Kärbers with a detection limit of 1 x 102 TCID50/ml: 
50

= 
 ⋅ 10((.)) 
x: Extrapolation factor arising from the volume of virus dilution used per well 
A: Value of the last dilution step where all eight wells showed syncytia formation 
B: Summation of the proportion of positive wells including both the last 100% up to the first 0% infectious dilution 
2.4.4 Cell viability assay 
For viability analysis of virus infected cells, the RealTime-GloTM MT Cell Viability Assay (Promega) 
was used according to the manufacture’s protocol. 2 x 104 L-428 or KM-H2 cells were seeded into 
96-well plates. Cells were infected in triplicates with an MOI of 1 with VSV-CD30 or MV-CD30.  
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In addition, cells were treated with OptiMEM or VP-SFM as mock control. 4 h post infection, NanoLuc® 
luciferase and the cell-permeant pro-substrate MT Cell Viability Substrate were added and 
incubated at 37°C. To monitor cell viability, luciferase signals were quantified at the microplate 
luminometer (Berthold Technologies) 24 h and 48 h post infection. Pure medium served as blank 
and cell viability was normalized to uninfected control cells. 
 
2.5 Experimental mouse work 
All animal experiments were carried out in compliance with the regulations of the German animal 
protection law. 6-8 weeks old female NOD.Cg.PrkdcscidIL2rgtmWjl/SzJ (NSG) mice were purchased from 
Charles River. Mice were housed in the animal facility in individually ventilated cages and handled 
under a laminar flow hood. 
2.5.1 Administration of tumor cells 
L-428 and KM-H2 tumor cells were cultured as described in chapter 2.3.1. Then, desired amount of 
cells were pooled, pelleted at 300xg for 5 min and washed with PBS. Cell number was determined 
and resuspended in a defined volume of PBS to the desired cell density for implantation. To implant 
subcutaneous (s.c.) tumors, mice were anesthetized with 2% isoflurane using an anesthetic machine 
with an isoflurane vaporizer and oxygen concentrator (indulab-vet). 100 µl of tumor cell suspension 
were s.c. injected into the flank using a BD MicroFine 1 ml U100 29G Insulin syringe. For pilot 
experiments, 5x106 KM-H2 or L-428 were s.c. injected per NSG mouse. For main experiments, 1x107 
KM-H2 cells pre-mixed with an equal amount of Corning® Matrigel® Basement Membrane Mix were 
s.c. injected per NSG mouse. Tumor growth was monitored by palpation and later using a digital 
caliper. Tumor size was calculated according to the volume of an ellipsoid by the following 
equation: 
   !"# =
 $%ℎ!# × (ℎ (%ℎ!#))
2
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For implantation of disseminated tumors, NSG mice were pre-warmed using an infrared lamp in 
order to dilate the veins and transferred to a mouse-restrainer. 200 µl of tumor cell suspension 
containing 2x106 KM-H2-luc cells was intravenously (i.v.) injected into one of the lateral tail veins 
using a BD MicroFine 1 ml U100 29G Insulin syringe. The extent of tumor progression was analyzed 
by in vivo imaging (Chapter 2.5.3). 
Differences in tumor growth were quantified afterwards via calculation of area under the curve 
(AUC) (Duan et al. 2012). 
2.5.2 Virus administration  
When s.c. L-428 and KM-H2 tumors reached a specified volume, they were intratumorally (i.t.) 
injected with VSV-CD30 or MV-CD30. The desired amount of virus was diluted in VP-SFM (VSV-CD30) 
or OptiMEM (MV-CD30) to a total volume of 50 µl per tumor. Mice were anesthesized with 2% 
isoflurane using an anesthetic machine with an isoflurane vaporizer and oxygen concentrator 
(indulab-vet). 
For i.v. injections, 200 µl VSV-CD30 was injected into one of the lateral tail veins as described in the 
previous chapter. VP-SFM served as mock control. 
2.5.3 In vivo imaging 
In vivo imaging is a method for non-invasively visualization of luciferase expressing cells in living 
mice. Luciferase signals were measured using the IVIS® Spectrum (Perkin Elmer) and analyzed using 
the Living Image Software (Perkin Elmer). Prior to measurement, 150 µg D-luciferin per gram body 
weight was injected intraperitoneally into mice. Mice were anesthetized with 2% isoflurane using a 
XGI-8 Gas Anesthesia system (Perkin Elmer). Imaging data were obtained 10 min after luciferin 
injection. 
2.5.4 Immunofluorescence staining of cryo slices 
Subcutaneous tumors were explanted, cut into two halves and fixed in 4% formaldehyde in PBS 
(Roti®-Histofix 4%) for at least 24 h. Next, tissue was dehydrated in 30% sucrose (PBS) and then 
embedded in optimum cutting temperature (O.C.T.) medium for snap freezing. Specimens were 
stored at -80°C. 
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Slices of 8 μm thickness were obtained with a cryostat (Leica CM1900) and dried at room 
temperature overnight. Slices were permeabilized with 0.2% Triton X100/PBS for 10 min and blocked 
with 5% donkey serum for 30 min at room temperature. For staining against GFP, slices were 
incubated with the rabbit α-GFP antibody (Invitrogen) overnight at 4°C, followed by incubation with 
the donkey α-rabbit Cy2-coupled secondary antibody (Jackson ImmunoResearch). For 
immunofluorescence staining against CD31, slices were incubated with the rat α-mouse CD31 
antibody (Dianova) overnight at 4°C, followed by incubation with the donkey α-rat Alexa647-
coupled secondary antibody (Jackson ImmunoResearch). Sections were mounted using 
Fluoroshield™ DAPI containing mounting media (Sigma-Aldrich). 
2.5.5 Virus recovery 
VSV-CD30 treated s.c. tumor were explanted, placed onto a 70 µm cell strainer and pushed through 
the cell strainer using the plunger end of a syringe. Next, the strainer was washed with DMEM+PenStrep 
medium and cells were pelleted for 5 min at 300xg and 4°C. Tumor cell suspension was transferred 
to Vero-αHis cells and incubated for 48 h at 37°C. After two days, cell culture of Vero-αHis cells and 
tumor cell suspension was analyzed by fluorescence microscopy for GFP expression. 
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3 Results 
This thesis characterizes two CD30-targeted oncolytic viruses as a new treatment option for CD30+ 
cHL. One is an oncolytic MV the other is VSV-MV chimera specific for CD30. The generation of those 
CD30-targeted oncolytic viruses was described in a previous work (Hanauer 2015). After 
demonstrating their specificity and their ability to infect and lyse CD30+ cHL cell lines in vitro, 
suitable tumor mouse models were set up. Having two cHL xenograft mouse models at hand, the 
therapeutic activities of both MV-CD30 and VSV-CD30 were investigated via different virus 
application routes. Finally, the susceptibility of other CD30+ tumor cell lines (anaplastic large cell 
lymphoma) for the infection with CD30-targeted viruses was evaluated in vitro. 
 
3.1 CD30-targeted oncolytic viruses 
In the previous work, a CD30-targeted measles virus (MV-CD30) and a vesicular stomatitis virus 
(VSV-CD30) were generated with the aim of selectively destroying CD30+ cHL cells (Hanauer 2015). 
Both rely on the recently described scFv HRS3opt2#2 (Friedel et al. 2015) as CD30-specific binding 
domain. Its coding sequence is fused to that of MV hemagglutinin (H) at the C terminal end. To 
achieve retargeting, the MV-H is blinded for the attachment to natural MV receptors CD46, Nectin-4 
and SLAM (Nakamura et al. 2005). For MV-CD30, the unmodified MV-H gene is exchanged against the 
coding sequence of Hmut-CD30-scFv (Figure 3.1). In case of VSV-CD30 the VSV glycoprotein G gene is 
replaced by reading frames of the MV fusion protein (F) and Hmut-CD30scFv. Recombinant VSV-MV 
contain an unmodified H protein, as well as MVNse both serving as parental virus controls. The usage 
of CD30 as an entry receptor by the generated CD30-targeted viruses had been analyzed before by 
infection of co-cultures of target and non-target cells as well as through blocking infection by 
soluble CD30-Fc protein (Hanauer 2015). New virus stocks of both CD30-targeted viruses as well as 
their parental viruses were produced in the beginning of this thesis. 
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Figure 3.1: Genomic organization of CD30-targeted and untargeted parental viruses 
MV-H protein blinded for natural MV receptors CD46 and SLAM (indicated by *) to generate Hmut is fused to a CD30-specific 
scFv with a C-terminal hexa-His-tag (H6) (CD30-scFv). For VSV-MV the VSV glycoprotein G reading frame is replaced with 
those of MV-F and MV-H, while VSV-CD30 encodes for MV-F and MV-Hmut-CD30-scFv. All virus genomes encode the reporter 
protein eGFP. Modified from (Hanauer 2015; Hanauer et al. 2018).  
Following initial rescue of virus particles, single virus clones were generated by picking isolated 
syncytia after three rounds of passaging as described in chapter 2.4.1 and 2.4.2. Selected clones 
were further propagated on Vero-αHis cells. These cells are CD30- but display a Hexa-His-tag (H6)-
specific antibody which can be used as entry receptor by both retargeted viruses due to a C-terminal 
H6 fused to Hmut-CD30scFv. All recombinant MV stocks were generated from infected Vero-αHis cell 
lysates. 
Viral growth kinetics of all generated viruses had been investigated (Hanauer 2015). VSV-CD30 
replicates with VSV-like kinetics to high titers in supernatant of infected Vero-αHis cells. Therefore, 
the purification of VSV-CD30 out of supernatant of infected cells was established in this thesis 
instead of using cell lysates. For this, Vero-αHis cells were seeded in a T175 cell culture flask in 
VP-SFM supplemented with 1% glutamine and infected with an MOI of 0.01. Infected cells were 
cultured for 24 h at 37°C, followed by 24 h at 32°C. After incubation, supernatant of infected cells 
was collected and pooled. Cell debris in the supernatant were first removed via centrifugation for 
5 min at 3000xg and second by filtration through a 0.45 µm filter. Concentration of virus containing 
supernatant was performed using an Amicon 100K size exclusion filter. Volume was concentrated 
to 500 µl per size exclusion filter after centrifugation at 3000xg for 1.5 h. After concentration, virus 
stocks were sterile filtrated through a 0.22 µm filter and titrated on Vero-αHis cells. 
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Figure 3.2: Viral titers of CD30-targeted viruses 
Cell-associated and supernatant (SN) titers of MV-CD30 and VSV-CD30 stocks represented by the 50 % Tissue Culture 
Infective Dose (TCID50/ml). n=6, error bars: mean ± SD. 
Recombinant cell-associated VSV-CD30 was produced to titers up to 5.0 x 108 TCID50/ml (Figure 3.3), 
whereas VSV-CD30 purified out of supernatant grew to highest titers up to 1 x 109 TCID50/ml. In 
contrast, MV-CD30 grew to maximal titers in the range of 1 x 108 TCID50/ml. 
3.1.1 Characterization of CD30-targeted viruses 
After generation of CD30-targeted viruses, the molecular composition of viral particles was 
analyzed. For this purpose, Western blot analysis for verification of the incorporation of MV-H and 
–F proteins was performed.  
 
Figure 3.3: MV-glycoprotein expression of CD30-targeted viruses 
Western blot analysis of 5 x 105 TCID50 virus stock solution of CD30-targeted (MV-CD30, VSV-CD30) and untargeted (MV, 
VSV-MV) viruses for expression of MV-H and –F protein using antibodies recognizing the cytoplasmic tail of MV-H or MV-F. 
As negative control, wildtype VSV was used. Modified from (Hanauer et al. 2018). 
Immunoblots of viral stocks revealed that VSV-CD30 and VSV-MV both contained the MV 
glycoproteins H and F (Figure 3.3).  
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Due to the fusion of the CD30-scFv protein, electrophoretic mobility of Hmut-CD30-scFv was reduced 
compared to H, resulting in a typical signal shift. This was also the case for stocks of MV-CD30 which 
were analyzed along with MV stocks.  
3.1.2 Susceptibility of human classical Hodgkin lymphoma cell lines 
After assessing the selectivity of CD30-targeted viruses, the next focus was the susceptibility of 
cHL cells. Since primary HRS-cell cultures are unavailable, cHL-derived, continuously growing cell 
lines were used as a model. The selected cell lines are covering two different subtypes of cHL, 
nodular sclerosis (L-428) and mixed cellularity (KM-H2) and are long-standing adequate models for 
HRS cell physiology with tumorigenic potential (Mathas et al. 2006; Steidl et al. 2011; Tiacci et al. 
2012). First, the expression levels of the target receptor CD30 and the natural MV receptors SLAM 
and CD46 on L-428 and KM-H2 cells were determined by flow cytometry. Both cell lines were 
infected with CD30-targeted and the parental viruses. 
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Figure 3.4: Susceptibility of human cHL cell lines L-428 and KM-H2 
(A) Flow cytometry analysis of human cHL cell lines L-428 and KM-H2 for CD30, CD46 and SLAM expression. Cells were 
stained with a PE-labeled mouse CD30 antibody, a PE-labeled mouse CD150 (SLAM) antibody and a (FITC)-labeled mouse 
CD46 antibody. (B) Human cHL cell lines L-428 and KM-H2 were infected with CD30-targeted viruses and untargeted 
parental viruses at an MOI of 1 and analyzed by fluorescence microscopy 24 hours (VSV/MV, VSV-CD30) or 72 hours (MV, 
MV-CD30) post infection. Scale bar=200 µm. Modified from (Hanauer et al. 2018). 
Flow cytometry analysis showed that L-428 and KM-H2 cells expressed CD30 as well as CD46 in a 
similarly high amount, but hardly any SLAM (Figure 3.4A). Both CD30-targeted viruses as well as 
their untargeted parental viruses readily infected both cHL cell lines and induced the formation of 
large syncytia (Figure 3.4B). Finally, the cytotoxic activity of MV-CD30 and VSV-CD30 infection on 
both cHL lines were evaluated. 
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Figure 3.5: Killing assay of human cHL cell lines L-428 and KM-H2 
Cell viability of human classical HL cell lines L-428 and KM-H2 after infection with MV-CD30 or VSV-CD30 with an MOI of 
1. Viability was determined until 48 h post infection using the RealTime-Glo MT Cell Viability Assay and is presented as 
percentage to mock control. n=3, error bars: mean ± SEM. Modified from (Hanauer et al. 2018). 
MV-CD30 infection did not kill L-428 cells within 48 h, while VSV-CD30 infection reduced cell 
viability to 50% after 24 h and to 30% after 48 h (Figure 3.5). Similar to what observed with L-428 
cells, MV-CD30 infection did not reduce viability of KM-H2 cells at all during the observation period. 
In contrast, VSV-CD30 reduced cell viability to 60% after 24 h and to 48% after 48 h. Comparison of 
both cHL cell lines indicated a slightly higher killing activity of VSV-CD30 on L-428 cells than on 
KM-H2 cells. Overall, VSV-CD30 was more potent in vitro killing both L-428 and KM-H2 cells than 
MV-CD30. 
3.1.3 Specificity of CD30-targeted oncolytic viruses 
In this thesis, CD30 on cHL cells was used as a specific entry receptor for MV-CD30 and VSV-CD30. 
However, CD30 is not a cHL-exclusive tumor marker. For instance, activated T lymphocytes could 
express CD30 upon viral infections (Horie, R. and Watanabe, T. 1998). Those activated CD30+ 
T lymphocytes represent a potential target population which can be infected by CD30-targeted 
oncolytic viruses. Therefore, the infection of CD30+ T lymphocytes with MV-CD30 and VSV-CD30 was 
investigated first. To do so, CD30 expression upon activation of T lymphocytes was verified and 
CD25 was stained to monitor the activation of T lymphocytes. 
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Figure 3.6: CD30 expression on activated T lymphocytes  
Flow cytometry analysis of human PBMC that were cultured in absence (upper panel) or presence of the activating agents 
α-CD3/α-CD28 and IL-2 (lower panel) for CD3, CD25 and CD30 expression. Cells were stained with a Pacific-Blue-labeled 
mouse CD3 antibody, an APC-Cy7-labeled mouse CD25 antibody and a PE-labeled mouse CD30 antibody. Modified from 
(Hanauer et al. 2018). 
T lymphocytes cultivated in the presence of α-CD3/α-CD28 and IL-2 were successfully activated 
indicated by detection of CD25 (Figure 3.6). Following activation of T lymphocytes, CD30 was 
upregulated. Since CD30 expression as described in literature was confirmed, infection of activated 
T lymphocytes with CD30-targeted viruses and their parental viruses was performed. 
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Figure 3.7: Infection of CD30+ T lymphocytes  
Activated PBMC expressing CD30 were infected with CD30-targeted viruses or untargeted parental viruses with an MOI of 
0.1. GFP expression was monitored by fluorescence microscopy 24–96 h post infection.  
Scale bar=200 µm. Modified from (Hanauer et al. 2018). 
Both VSV-CD30 and VSV-MV did not infect activated T lymphocytes within 96 hpi (Figure 3.7). 
MV-CD30 infected some cells, which subsequently build syncytia-like structures. Still, the infection 
seemed not to spread within the culture over time. Only MV infection spread within 96 hpi, leading 
to the formation of larger syncytia. Flow cytometry analysis of infected cells revealed the same 
pattern on single cell level (Figure 3.8). 
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Figure 3.8: Flow cytometry analysis of infected CD30+ T lymphocytes 
Flow cytometry analysis of activated living PBMC infected with CD30-targeted viruses or untargeted parental viruses (MOI 
of 1) after 72 hpi for CD3 and GFP expression. Cells were stained with an eFluor™-780-labeled Fixable Viability Dye and a 
Pacific-Blue-labeled mouse CD3 antibody. Modified from (Hanauer et al. 2018). 
To sum up, T lymphocytes were completely protected from VSV-CD30 as well as VSV-MV infection 
despite the presence of CD30 as entry receptor. Partial susceptibility of T lymphocytes for MV 
infection is reduced by retargeting MV to CD30. 
 
3.2 Setting up a tumor mouse model for in vivo characterization of VSV-CD30 
To evaluate the oncolytic potential of VSV-CD30 in comparison to MV-CD30 on cHL cells in vivo, a 
suitable tumor mouse model had to be established. For proof of concept, a s.c. growing human cHL 
tumor was generated in immunodeficient NSG mice from the previously introduced cell lines. 
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3.2.1 Tumor growth of subcutaneous L-428 vs KM-H2 tumors 
Both cHL cell lines L-428 and KM-H2 were shown to be susceptible for infection with CD30-targeted 
viruses in vitro. However, only VSV-CD30 infection had induced killing of both tumor cell lines, 
whereas MV-CD30 had not. Therefore, investigation of the oncolytic activity of VSV-CD30 in a tumor 
mouse model was focused first. L-428 or KM-H2 cells were implanted s.c. into NSG mice. Once 
tumors reached a size of 100 mm³, three i.t. injections of 3 x 108 TCID50 of VSV-CD30 in total were 
performed within one week. 
 
Figure 3.9: Tumor growth curves of s.c. L-428 and KM-H2 tumors 
NSG mice were s.c. implanted with 5 x 106 L-428 or KM-H2 cells. 14 days post cell transplantation, mice received three i.t. 
injections of VSV-CD30 over a period of five days covering a total dose of 3 x 106 TCID50 (dashed lines). Control animals 
(mock) were injected with an equal volume of VP-SFM. Tumor growth curves of individual mice and an overlay of the 
mean of both groups (error bars: mean ± SD) are shown. L-428: VSV-CD30 and mock, n=8. KM-H2: VSV-CD30, n=4; mock, 
n=2. 
L-428 tumors grew more homogenously than KM-H2 tumors (Figure 3.9). Only 6 out of 16 (37%) 
implanted KM-H2 tumors grew, with delayed kinetics compared to L-428 tumors. However, 
VSV-CD30 treatment induced a strong tumor growth inhibition in KM-H2 tumors, but not in L-428 
tumors.  
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Since tumor sizes were measured manually with a caliper during the experiment, tumor weight and 
size were measured again at the end of the experiment to obviate any inaccuracies. 
 
Figure 3.10: Final analysis of s.c. L-428 and KM-H2 tumors treated with VSV-CD30 
14 days after the last virus injection, s.c. L-428 and KM-H2 tumors were explanted and analyzed for (A) Tumor volume and 
(B) Tumor weight. L-428: VSV-CD30 and mock, n=8. KM-H2: VSV-CD30, n=4; mock, n=2. Unpaired t test: *** p <0.001, ** p 
<0.01, * p<0.05. Error bars: mean ± SD. 
Final analysis revealed a slight difference between VSV-CD30 and mock treated L-428 tumors when 
measuring the tumor volume. Determination of tumor weight however confirmed that this 
difference was not significant (Figure 3.10). In contrast, volumes of KM-H2 tumors treated with 
VSV-CD30 were significantly smaller than mock treated tumors. Difference in tumor growth of 
VSV-CD30 to mock treated KM-H2 tumors proved even greater when the tumor weight was 
examined. Altogether, the data from final analysis was consistent with the tumor size 
measurements during the experiment. To verify that VSV-CD30 was present in i.t. treated tumors, 
L-428 and KM-H2 tumors were dissociated and an overlay of tumor cell suspension on Vero-αHis 
cells was performed.  
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Figure 3.11: Virus recovery from i.t. treated L-428 and KM-H2 tumor tissue 
Intratumorally (i.t.) VSV-CD30 treated s.c. L-428 and KM-H2 tumors were explanted 14 days after the last virus injection 
and dissociated mechanically through a cell strainer. Tumor cell suspensions were overlayed on Vero-αHis cells and 
analyzed for GFP expression by fluorescence microscopy 48 hours post infection.  
Scale bar=200 µm. 
From none of the VSV-CD30 treated L-428 tumors, virus was recovered (Figure 3.11), indicating that 
no replicating virus had remained in the tumor tissue. As expected from the tumor growth 
inhibition, in all four VSV-CD30 treated KM-H2 tumors virus was recovered from tumor cell 
suspension. To assess the targeting capacity of VSV-CD30 in the KM-H2 tumor mouse model, the 
experimental set-up was repeated. KM-H2 cells were implanted s.c., but this time, VSV-CD30 was 
injected intravenously instead of intratumorally.  
 
Figure 3.12: Virus recovery from i.v. treated KM-H2 tumor tissue  
NSG mice were s.c. implanted with 5 x 106 KM-H2 cells. 14 days post cell implantation mice received three i.v. injections of 
VSV-CD30 over a period of five days covering a total dose of 3 x 108 TCID50. Treated s.c. KM-H2 tumors were explanted 14 
days post last virus injection and dissociated mechanically through a cell strainer. Tumor cell suspension was overlayed 
on Vero-αHis cells and analyzed for GFP expression by fluorescence microscopy 48 hours post infection. n=3. Scale 
bar=200 µm. 
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Remarkably, similar to i.t. treated KM-H2 tumors, replicating VSV-CD30 could also be recovered from 
of all i.v. treated tumors (Figure 3.12). 
Taken together, KM-H2 cells seemed to respond better than L-428 cells to VSV-CD30 treatment 
in vivo, but tumor growth of s.c. KM-H2 had to be optimized. 
3.2.2 Improving KM-H2 tumor growth using Matrigel 
Antitumoral efficacy of VSV-CD30 was demonstrated to be stronger on s.c. KM-H2 tumors than on 
L-428 tumors, but the tumor growth was unstable. Subsequently, the next step was to optimize the 
tumor growth of s.c. KM-H2 tumors. An extracellular matrix-based hydrogel (“Matrigel”) was used to 
stabilize growth of s.c. injected KM-H2 cells at the site of injection. To do so, KM-H2 cells were mixed 
with Matrigel (1:1) or left untreated as control and subsequently implanted s.c. into NSG mice. In 
contrast to the previous experimental setting, tumors were already injected three times i.t. with 
3 x 108 TCID50 of VSV-CD30 within one week when they reached a size of 50 mm³ instead of 100 mm³. 
 
Figure 3.13: Tumor growth of s.c. KM-H2 tumor in combination with Matrigel matrix 
NSG mice were s.c. implanted with 1 x 107 KM-H2 cells mixed with Matrigel (+) or left untreated as mock control (-). 13 days 
post cell transplantation, mice ((+) Matrigel) received three i.t. injections of VSV-CD30 over a period of five days covering 
a total dose of 3 x 106 TCID50 (dashed lines). Control animal (mock) was injected with an equal volume of VP-SFM. Tumor 
growth curves of individual mice are shown. VSV-CD30, n=2; mock, n=1. 
Tumor growth curves show that s.c. implanted KM-H2 cells without Matrigel did not grow at all 
(Figure 3.13A). In contrast, all mice implanted s.c. with KM-H2 cells in combination with Matrigel 
developed a tumor. In addition, s.c. KM-H2 tumors implanted with Matrigel responded to VSV-CD30 
treatment with a tumor growth delay (Figure 3.13B), indicating that the Matrigel matrix did not hinder 
oncolysis.  
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To further characterize viral replication in KM-H2 Matrigel tumor tissue, VSV-CD30 and blood vessels 
(CD31) were detected by immunofluorescence. In detail, KM-H2 cells mixed with Matrigel were 
implanted s.c. into NSG mice. VSV-CD30 was either applied i.t. (1 x 106 TCID50) or i.v. (1 x 108 TCID50). 
Afterwards, VSV-CD30 injected tumors were cut in sections and stained for GFP and CD31. 
 
Figure 3.14: Detection of VSV-CD30 in s.c. KM-H2 tumor tissue 
Subcutaneously (s.c.) implanted KM-H2 tumors were treated i.t. with 1 x 106 TCID50 of VSV-CD30 (top row), i.v. with 1 x 108 
TCID50 VSV-CD30 (middle row) or OptiMEM as mock control (bottom row), respectively. 14 days post treatment, tumors 
were removed and cut in sections. GFP+ cells were detected by immunofluorescence staining using a polyclonal GFP 
antibody and a Cy2-labeled secondary antibody. Murine blood vessels were detected by immunofluorescence staining 
using a polyclonal CD31 antibody and an Alexa-Fluor647-labeled secondary antibody. One representative section out of 
ten GFP positive sections is shown. Scale bar=200 µm. Adapted from (Hanauer et al. 2018). 
Slices of mock treated tumors showed expression of CD31 which indicated blood vessel formation, 
but no GFP expression for any infectious spots (Figure 3.14). For both virus application routes, GFP 
expression indicated infectious areas of VSV-CD30 in all sections stained.  
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Remarkably, infectious areas were equally distributed independent from virus application route. 
Similar to mock treated tumors, VSV-CD30 treated tumors showed expression of CD31 for blood 
vessel formation potentially facilitating the spread of VSV-CD30 within the tumor. 
In conclusion, s.c. KM-H2 tumors grew more homogenously when implanted with Matrigel. In 
addition, VSV-CD30 was detected within the tumor tissue independently from Matrigel environment 
or route of administration. 
 
3.3 Antitumoral activity of CD30-targeted viruses in vivo 
Based on the aforementioned factors, KM-H2 cells are more suitable than L-428 for analysis of 
VSV-CD30 in vivo as model for cHL. After optimizing the tumor growth, this cHL cell line was used 
for the subsequent characterization of the antitumoral activity of CD30-targeted viruses in the 
xenograft mouse model. 
3.3.1 Oncolytic activity of CD30-targeted viruses after intratumoral administration 
After having established the KM-H2 tumor model, the comparison of antitumoral activities of 
VSV-CD30 vs MV-CD30 was examined next. For this purpose, KM-H2 cells mixed with Matrigel were 
implanted s.c. into NSG mice. Once tumors reached a size of 50 mm³, three i.t. injections of 3 x 106 
TCID50 (MV-CD30 or VSV-CD30) in total were performed within one week. To analyze the impact of 
the dosage, one group received 3 x 108 TCID50 of VSV-CD30 in total within one week. 
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Figure 3.15: Tumor growth curves of s.c. KM-H2 tumors i.t. treated with VSV-CD30 and MV-CD30 
NSG mice were s.c. implanted with 1 x 107 KM-H2 cells mixed with Matrigel. 13 days post cell transplantation, mice received 
three i.t. injections over a period of five days covering a total dose of 3 x 106 TCID50 (MV-CD30, VSV-CD30 low dose) or 
3 x 108 TCID50 (VSV-CD30 high dose (+)) (dashed lines). Control animals (mock) were injected with an equal volume of 
VP-SFM. Tumor growth curves of individual mice are shown till a tumor size >800 mm3 was reached. MV-CD30, n=7; VSV-
CD30 low dose, n=8; VSV-CD30 high dose (+), n=8; mock, n=8. 
Mock treated tumors grew unaffectedly and exponentially (Figure 3.15). MV-CD30 treated tumors 
showed only a slight tumor growth delay compared to mock treated controls. Remarkably, 
VSV-CD30 treatment in both doses completely inhibited tumor growth over several weeks. One 
VSV-CD30 low dose treated mouse went into full remission initially. It relapsed on day 55 post 
transplantation. Application of VSV-CD30 in the high dose resulted in the strongest tumor growth 
delay, with two mice that went into full remission initially. One of these mice relapsed on day 59, 
the other on day 62 post transplantation. Consequently, slowing of tumor growth was not 
permanent in VSV-CD30 treated mice. To quantify differences between the treatment groups, the 
differences in area under the curve (AUC) as well as survival of tumor bearing mice were determined. 
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Figure 3.16: Quantification of AUC and survival analysis of KM-H2 tumor-bearing mice 
NSG mice were s.c. implanted with 1 x 107 KM-H2 cells mixed with Matrigel. 13 days post cell transplantation, mice received 
three i.t. injections over a period of five days covering a total dose of 3 x 106 TCID50 (MV-CD30, VSV-CD30 low dose) or 
3 x 108 TCID50 (VSV-CD30 high dose (+)) (dashed lines). Control animals (mock) were injected with an equal volume of 
VP-SFM. (A) Average tumor growth curves of MV-CD30, VSV-CD30 low dose, VSV-CD30 high dose or mock treated mice 
until day 41 post transplantation. (B) Areas under the curves (AUC) shown in (a). One-way ANOVA test (Multiple 
comparisons), **** p <0.0001. (C) Kaplan-Meyer plot survival analysis. Logrank test (Bonferroni adjusted), *** p <0.001, ** p 
<0.01. MV-CD30, n=7; VSV-CD30 low dose, n=8; VSV-CD30 high dose, n=8; mock, n=8. Error bars: mean ± SEM. Modified from 
(Hanauer 2015; Hanauer et al. 2018). 
AUC determination revealed that the tumor volume of VSV-CD30 treated tumors was significantly 
smaller than that of MV-CD30 treated tumors when both were treated with an equivalent viral dose 
(Figure 3.16A, B). In correlation with the tumor growth inhibition, tumor-bearing mice survived 
significantly longer when treated with VSV-CD30 than MV-CD30 (Figure 3.16C). The prolonged 
survival of tumor bearing mice was even more pronounced when VSV-CD30 was applied at the 
higher dose. This data indicate that there is a dose relation of VSV-CD30 treatment. 
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3.3.2 Oncolytic activity of CD30-targeted viruses after intravenous administration 
Since VSV-CD30 was retargeted to CD30+ cells, it was expected that systemic administration would 
lead to a similar oncolytic effect compared to i.t. application. Previous experiments had already 
confirmed that VSV-CD30 can be detected in s.c. cHL xenograft tumor tissue when applied 
intravenously. Subsequently, the oncolytic potential in combination with the targeting capacity of 
VSV-CD30 was verified. The same s.c. xenograft KM-H2 mouse model as before was used, but 
VSV-CD30 was applied i.v. instead of i.t.. KM-H2 cells mixed with Matrigel were s.c. implanted into 
NSG mice. Once tumors reached a size of 50 mm³, mice received three i.v. injections of 3 x 108 TCID50 
of VSV-CD30 in total within three weeks. 
 
Figure 3.17: Tumor growth curves of s.c. KM-H2 tumors i.v. treated with VSV-CD30 
NSG mice were s.c. implanted with 1 x 107 KM-H2 cells mixed with Matrigel. 14 days post cell transplantation, a total dose 
of 3 x 108 TCID50 of VSV-CD30 split in three aliquots was systemically injected weekly (dashed lines). Control animals 
(mock) were injected with an equal volume of VP-SFM. Tumor growth curves of individual mice are shown until a tumor 
size >800 mm3. VSV-CD30, n=8; mock, n=6. 
Again, mock treated tumors grew unaffectedly (Figure 3.17). Remarkably, even after systemic 
application VSV-CD30 was able to inhibit tumor growth over several weeks compared to mock 
treated tumors. Similar to the results obtained for i.t. application of VSV-CD30, the slowed down 
tumor growth was not permanent and mice relapsed around day 32 post transplantation. To 
quantify the differences, AUCs were determined. 
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Figure 3.18: Quantification of AUC of KM-H2 tumor-bearing mice 
NSG mice were s.c. implanted with 1 x 107 KM-H2 cells mixed with Matrigel. 14 days post cell transplantation, a total dose 
of 3 x 108 TCID50 of VSV-CD30 split in three aliquots was systemically injected weekly (dashed lines). Control animals 
(mock) were injected with an equal volume of VP-SFM. (A) Average tumor growth curves of VSV-CD30 or mock treated 
mice until day 64 post transplantation. (B) Areas under the curves (AUC) shown in (a). Unpaired t test, **** p <0.0001. VSV-
CD30, n=7; mock, n=8. Error bars: mean ± SEM. Modified from (Hanauer 2015; Hanauer et al. 2018). 
Quantification of AUC reveled that tumor sizes of i.v. VSV-CD30 treated tumors were significantly 
smaller than mock treated ones (Figure 3.18). When the last mock treated mouse had to be sacrificed 
all VSV-CD30 treated mice were still alive. This also indicates a clear survival benefit with VSV-CD30 
even with i.v. treatment. Altogether, the tumor growth inhibition pattern was comparable to i.t. 
treated tumors. 
In conclusion, VSV-CD30 showed a high antitumoral efficacy in the s.c. cHL xenograft mouse model 
independent of the route of administration.  
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3.4 Analyzing VSV-CD30 in a disseminated KM-H2 tumor model 
Up to now, a xenograft tumor mouse model in which cHL cells were growing to large s.c. tumors 
was used for examining the oncolytic potential of VSV-CD30. However, in early stages cHL is rather 
affecting peripheral lymph nodes in patients. In late stages, metastasis in liver, lung and bone 
marrow can be found as well (Küppers 2012). Therefore, a tumor mouse model reflecting the 
clinically relevant tumor burden was needed to further characterize the potential applications of 
CD30-targeted VSV. For this purpose, a xenograft model in which KM-H2 tumors are systemically 
injected for disseminated growth was established. For non-invasive monitoring of tumor growth 
in vivo, KM-H2 cells stably expressing the luciferase gene (luc) had to be generated first. 
3.4.1 Generation of KM-H2-luc cells 
KM-H2-luc cells were generated by transduction of parental KM-H2 cells with an HIV-1-derived LV 
pseudotyped with VSV-G, encoding the firefly luciferase and a puromycin resistance. Selection of 
transduced cells was performed using puromycin. Luciferase expression of KM-H2 cells was 
afterwards verified in a luciferase assay.  
 
Figure 3.19: Generation of KM-H2-luc cells and infection with VSV-CD30 
(A) Luciferase signals of KM-H2-luc cells stably expressing the luciferase reporter gene (luc). 100-10 µl of VSV-G-HIV1-Puro-
Luc vector (Puro-luc-LV) were used for transduction of parental KM-H2 cells. Transduced cells were lysed and luciferase 
activity was determined. n=2, error bars: mean ± SD. (B) KM-H2-luc were infected with VSV-CD30 at an MOI of 1 and 
analyzed by fluorescence microscopy 24 hours post infection. Scale bar=200 µm. 
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KM-H2-luc cells generated using 50 µl of Puro-luc-LV showed the highest luciferase intensity 
(Figure 3.19A). Therefore, these cells were expanded and used for further experiments. Before 
investigating the disseminated tumor growth in vivo, KM-H2-luc cells were analyzed for their 
susceptibility for VSV-CD30 in vitro. Fluorescence microscopy pictures indicated that the 
expression of firefly luciferase did not influence the susceptibility of KM-H2-luc cells for VSV-CD30 
infection (Figure 3.19B). 
3.4.2 Setting up the injection regime in a multifocal KM-H2-luc model 
To monitor disseminated tumor growth in vivo, KM-H2-luc cells were injected i.v. into NSG mice in 
two different cell counts. Development of tumor foci was visualized by luciferase in vivo imaging 
over time. When luciferase signals were detectable, both mice implanted with KM-H2-luc cells were 
injected with 1 x 108 TCID50 of VSV-CD30. Luciferase signal intensities were quantified afterwards. 
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Figure 3.20: Setting up VSV-CD30 injection regime in a multifocal KM-H2-luc model 
NSG mice were implanted i.v. with 1 x 106 (mouse 1) or 2 x 106 (mouse 2) KM-H2-luc cells. Mouse 1 received one i.v. injection 
of 1 x 108 TCID50 VSV-CD30 on day 33 post cell transplantation (dpi) (B: purple dashed line). Mouse 2 received one i.v. 
injection of 1 x 108 TCID50 VSV-CD30 on 24 dpi (B: red dashed line). Control animal (PBS) was injected with an equal volume 
of PBS. (A) Luciferase imaging pictures of treated mice. Ventral view of all mice included in the experiment recorded at 
the indicated time points. Red arrows: Injection of VSV-CD30. (B) Total luciferase activities over time for each mouse.  
Luciferase signals were detected in both mice injected with KM-H2-luc cells, indicating successful 
tumor growth for both cell intensities used (Figure 3.20A). For mouse 1 tumor foci concentrated 
close to the injection site and for mouse 2 presumably in the liver and in the bone marrow. 
Interestingly, independent of tumor site and infused cell number, VSV-CD30 treatment induced a 
nearly complete tumor remission until the end of the observation period in both mice (Figure 3.20B). 
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3.4.3 Oncolytic activity of VSV-CD30 in a multifocal KM-H2-luc model 
Having shown that KM-H2-luc cells engrafted into NSG mice and tumor sites can be targeted with 
VSV-CD30, the next step was the analysis of the antitumoral efficacy in larger cohorts. Again, 
KM-H2-luc cells were i.v. implanted into NSG mice. Luciferase intensities reflecting the tumor 
burden were measured by in vivo imaging over time. When considerable luciferase signals were 
detected, all mice received three i.v. injections of 3 x 108 TCID50 of VSV-CD30 in total within 10 days. 
 
Figure 3.21: Oncolytic activity of VSV-CD30 in a multifocal KM-H2-luc model 
Luciferase imaging pictures of NSG mice implanted i.v. with 2 x 106 KM-H2-luc cells. Mice received three i.v. injections of 
VSV-CD30 covering a total dose of 3 x 108 TCID50 on day 18, 21 and 28 post cell transplantation (dpi). Control animals (mock) 
were injected with an equal volume of VP-SFM. Ventral view of all mice included in the experiment recorded at the 
indicated time points (dpi: days post implantation). Modified from (Hanauer 2015; Hanauer et al. 2018). 
Luciferase imaging pictures on day 14 post transplantation showed that KM-H2-luc cells had 
engrafted into all mice and concentrated in different organs (Figure 3.21). For some mice, signals 
concentrated at the injection site, for others presumably in the liver, in lung or in bone marrow. Up 
to day 26 post transplantation, tumor signals increased slowly and no differences between both 
treatment groups were detectable.  
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First responses to VSV-CD30 treatment were visible on day 33 post cell transplantation in five out 
of eight mice. On the last day of observation, at least those five mice showed substantial decreased 
luciferase signals, whereas the remaining three mice showed high luciferase signals concentrating 
in different organs, similar to mock treated mice. 
 
Figure 3.22: Kinetic of KM-H2 luc tumor burden in mock and VSV-CD30 treated mice 
NSG mice were intravenously (i.v.) implanted with 2 x 106 KM-H2-luc cells. Mice received three i.v. injections of VSV-CD30 
covering a total dose of 3 x 108 TCID50 on day 18, 21 and 28 post cell transplantation (dashed lines). Control animals (mock) 
were injected with an equal volume of VP-SFM. (A) Total luciferase activities over time for each individual mouse are 
shown as spider plots. (B) Quantified luciferase signals on day 46 are shown as logarithm of the total flux (p/sec). Unpaired 
t test, p=0.07 (ns). VSV-CD30, n=8; mock, n=6. Modified from (Hanauer 2015; Hanauer et al. 2018). 
Quantification of the total flux of luciferase intensity over the duration of the experiment 
demonstrated that VSV-CD30 treatment induced a delayed tumor growth in some mice (Figure 3.22 
A). However, comparing the luciferase intensities of VSV-CD30 vs mock treated mice at the endpoint 
of the experiment, the observed difference narrowly failed to be statistically significant (p=0.07). 
Still, VSV-CD30 showed oncolytic activity at least in some mice. These results were unexpected 
compared to the pilot experiment where VSV-CD30 treatment completely eliminated tumor burden. 
To eliminate inaccuracies, final analysis of KM-H2-luc mice treated with VSV-CD30 involved 
explantation and imaging of all organs to determine signal origin more precisely. 
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Figure 3.23: Final analysis of KM-H2-luc of mock and VSV-CD30 treated mice  
NSG mice were implanted i.v. with 2 x 106 KM-H2-luc cells. Mice received three i.v. injections of VSV-CD30 covering a total 
dose of 3 x 108 TCID50 on day 18, 21 and 28 post cell implantation. Control animals (mock) were injected with an equal 
volume of VP-SFM. Luciferase imaging pictures of two treated mice on day 46 dpi with all explanted organs, respectively. 
(A) mock treated mice. (B) VSV-CD30 treated mice. Lu: lung, L: liver; H: heart, K: kidney, S: spleen, T: tumor, G: gut, St: 
stomach.  
In the peritoneal cavity of mock treated mouse 1, a large solid tumor nodule was present (Figure 
3.23). Additionally, strong luciferase signals were observed in lung and gut. Mock treated mouse 2 
mainly showed signals in lung and liver. In contrast, VSV-CD30 treated mouse 1 showed luciferase 
signals concentrating in the lung again, but also in lymph nodes in the head region. In VSV-CD30 
treated mouse 2 KM-H2-luc cells formed a large tumor nodule on one kidney.  
To sum up, besides metastasis in different organs, also a large solid tumor structure was found in 
the peritoneal cavity. Therefore, final luciferase imaging more precisely illustrates the 
heterogeneous growth of KM-H2-luc tumors in this disseminated tumor model.  
To find another explanation for the unexpected results, a competition assay of VSV-CD30 using 
plasma of KM-H2-luc bearing mice in both treatment groups was performed. 
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3.4.4 Competition assay of VSV-CD30 
For cHL cells a certain amount of CD30 on the cell surface is described as cleaved by 
metalloproteinases, resulting in the release of soluble CD30 (sCD30) (Josimovic-Alasevic et al. 1989). 
VSV-CD30 is designed to bind to CD30 with a high affinity through the CD30-scFv targeting domain. 
If sCD30 is present, as it would be in the plasma of KM-H2-luc bearing mice, the CD30-scFv displayed 
on VSV-CD30 could potentially be blocked. To analyze if the plasma of KM-H2-luc bearing mice in 
both treatment groups contained any neutralizing agents for VSV-CD30, a competition assay was 
performed. In detail, VSV-CD30 was pre-incubated with plasma of tumor bearing mice which were 
treated either with VSV-CD30 or mock treated. Subsequently, pre-incubated VSV-CD30 was titrated 
on HT1080-CD30 target cells. 
 
Figure 3.24: Neutralization assay of VSV-CD30 with KM-H2-luc bearing mouse plasma 
NSG mice were i.v. implanted with 2 x 106 KM-H2-luc cells. Mice received three i.v. injections of VSV-CD30 covering a total 
dose of 3 x 108 TCID50 on day 18, 21 and 28 post cell transplantation. Control animals (mock) were injected with an equal 
volume of VP-SFM. On day 46 (final day), plasma of all treated mice (VSV-CD30, mock) was used for pre-incubation with 
1 x 106 TCID50 VSV-CD30. As positive control for competiton of VSV-CD30, soluble CD30-Fc protein (CD30-Fc) was used, PBS 
served as negative control. Titration of the pretreated viruses was done on HT1080-CD30 cells. Infectivity [%] is presented 
as percentage to NSG mouse plasma without KM-H2-luc burden. Unpaired t test, * p<0.05, ns p>0.05. Error bars: mean ± 
SD. VSV-CD30, n=8; mock, n=6. 
Neither mock nor VSV-CD30 treated KM-H2-luc bearing mouse plasma induced neutralization of 
VSV-CD30 compared to PBS and CD30-Fc controls (Figure 3.24). This data indicates that there was 
no blocking agent present in plasma of KM-H2-luc mice.  
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3.5 Susceptibility of CD30+ anaplastic large cell lymphoma cell lines 
After successful treatment of cHL xenografts, CD30-targeted viruses were also investigated for their 
therapeutic potential on another CD30+ tumor type. ALCL is a T cell derived NHL characterized by 
high CD30 expression. Continuous patient-derived cell lines for ALK+ (Karpas 299, SUDHL1) and ALK- 
(MAC-1) ALCL were used for the subsequent experiments. To start with, expression of CD30 the target 
receptor on the ALCL cell lines were determined by flow cytometry.  
 
Figure 3.25: CD30 expression in ALCL cell lines  
Flow cytometry analysis of human ALCL cell lines Karpas 299, SUDHL1 and MAC-1 for CD30 expression. Cells were stained 
with a PE-labeled mouse CD30 antibody. 
All ALCL cell lines expressed a high amount of CD30 (Figure 3.25). This high expression of the target 
receptor should result in all cell lines being susceptible for the infection with CD30-targeted 
viruses. First Karpas299, SUDHL1 and MAC-1 were infected with VSV-CD30.  
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Figure 3.26: VSV-CD30 infection of ALCL cell lines  
Human ALCL cell lines Karpas 299, SUDHL-1 and MAC-1 were infected with VSV-CD30 at an MOI of 1 and analyzed by 
fluorescence microscopy 24 and 48 hours post infection. Scale bar=200 µm. 
However, despite the high expression of CD30, Karpas 299 as well as SUDHL1 were not susceptible 
for VSV-CD30 infection at all (Figure 3.26). Within the MAC-1 cell clusters, two infectious spots were 
found 24 hpi. However, VSV-CD30 infection seemed not to spread within the culture 48 hpi. Next, 
Karpas 299 and MAC-1 were infected with MV-CD30.  
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Figure 3.27: MV-CD30 infection of ALCL cell lines 
Human ALCL cell lines Karpas 299 and MAC-1 were infected with MV-CD30 at an MOI of 1 and analyzed by fluorescence 
microscopy 48 and 72 hours post infection, respectively. Scale bar = 200 µm. 
Surprisingly, MV-CD30 readily infected both Karpas 299 as well as MAC-1 cells 48 hpi. Infected 
Karpas 299 cells formed small-sized syncytia, which were still present in the culture 72 hpi. MAC-1 
cells showed infectious spots all over the formed clusters 48 hpi, which were also partially still 
present 72 hpi.  
This data demonstrates that cHL cell lines differ from ALCL cell lines in that they seem to be more 
susceptible for infection with MV-CD30 than with VSV-CD30. 
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4 Discussion 
cHL is a hematopoietic malignancy with a characteristic cellular composition where only 1% of CD30+ 
tumor cells are embedded in a reactive immune cell infiltrate. Current treatment of cHL patients 
mainly relies on chemotherapy followed by radiotherapy, while treatment options for relapsed or 
refractory cHL are still inadequate. Based on the unique histological pattern, immunotherapy based 
concepts using CD30 as targeting molecule are in focus as new therapy approaches. As part of 
immunotherapy, oncolytic viruses have an inherent lytic nature and the potential to induce a local 
inflammation in the tumor microenvironment. CD30-targeted oncolytic viruses could be a powerful 
new therapy approach for cHL specifically redirected to infect and lyse CD30+ tumor cells. 
This thesis depicts the first proof-of-concept study for the therapeutic use of two CD30-targeted 
oncolytic viruses, MV-CD30 and VSV-CD30, against cHL using preclinical xenograft mouse models. 
Findings on specificity of MV-CD30 and VSV-CD30, killing capacity in vitro and oncolytic activity of 
CD30-targeted viruses in vivo were made. Furthermore, the possibility to expand the system to 
other CD30+ lymphomas was investigated. This data will support further preclinical testing of 
VSV-CD30 as a novel therapeutic agent for the treatment of cHL and other CD30+ malignancies. 
4.1 CD30 as viral entry receptor  
CD30 expression was first discovered in 1982, as Ki-1 antigen found on HRS cells of cHL (Stein et al. 
1985). Therefore, CD30 is a characteristic cell surface marker for HRS cells, as well as ALCL and a few 
NHL (Pierce and Mehta 2017). In this thesis, two oncolytic viruses using CD30 as entry receptor were 
characterized. 
CD30 (also known as TNFRSF8) belongs to the superfamily of tumor necrosis factor (TNF) receptors 
(Kumar and Younes 2014; Hansen et al. 2016). It is a 120-kDa type I transmembrane protein which 
encompasses a large elongated extracellular part containing six cysteine-rich pseudo-repeat motifs 
(Duckett et al. 1997). CD30 is activated by ligand binding of CD30L and leads to trimerization of the 
receptor, recruitment of signaling proteins and transducing of numerous effects (Horie, R. and 
Watanabe, T. 1998). CD30 lacks an intrinsic enzymatic domain. Signal transduction is exclusively 
mediated by several TNF receptor-associated factors (TRAF)-binding domains which are associated 
with the cytoplasmic domain. Several pathways can be activated including the activation of nuclear 
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factor kappa-b (NF-κB) and MAP kinases. In contrast to other members of the TNF receptor 
superfamily, the cytoplasmic domain of CD30 does not contain a death domain. Several pathways 
including promotion of cell proliferation and cell survival as well as anti-proliferative effects and 
cell death can be activated depending on cell type and co-stimulatory effects (Schneider and 
Hübinger 2002). 
To use CD30 as viral entry receptor, a CD30-specific scFv was optimized and fused to MV-H. The 
successful binding of MV-H-α-CD30 to soluble CD30-Fc protein was verified during its optimization 
(Friedel et al. 2016). This scFv proved to be highly stable and specific in mediating gene delivery by 
lentiviral vectors pseudotyped with these MV glycoproteins. Specificity of CD30-targeted viruses 
had been assessed on a panel of transgenic CHO-cells as wells as in a competition assay using 
soluble CD30-protein before using them for the infection of cHL and ALCL cells lines (Hanauer et al. 
2018; Hanauer 2015). 
CD30 is not only present on cHL cells but also on activated T lymphocytes upon viral infection or 
during autoimmune disease (Horie, R. and Watanabe, T. 1998). CD30+ T lymphocytes form a potential 
off-target population and were therefore investigated for their susceptibility for CD30-targeted 
viruses. However, in healthy cells, including T lymphocytes, viral infection induces antiviral 
mechanisms of the innate immune system for example the expression of type I IFN (Katze et al. 
2002). In contrast, many tumor cells accumulate defects in the innate immune system to escape 
the immune response. These defects render them sensitive towards infection especially with RNA 
viruses (Stojdl et al. 2003). Indeed, T lymphocytes were completely protected from infection with 
VSV-CD30 and VSV-MV despite the presence of CD30 on the cell surface and cultivation for several 
days. Only MVNse infected a few CD30+ cells (Figure 3.7, Figure 3.8). Infection of activated 
T lymphocytes by MVNSe was not unexpected. Wildtype MV as well as attenuated MV variants have 
a natural tropism for monocytic and lymphoid cells. Infection of activated T lymphocytes is based 
on the expression of SLAM as entry receptor which allows the first systemic spread of MV (Tatsuo 
et al. 2000; Schneider-Schaulies et al. 2001). Thus, CD30 targeting does not extend the tropism of 
VSV or MV to T lymphocytes. 
In this study, two different cHL cell lines covering two different patient cases, as well as three 
different ALCL cell lines were examined for the infection with CD30-targeted viruses. All cell lines 
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expressed a high amount of CD30, which rendered them susceptible for the infection. Both cHL cell 
lines tested L-428 and KM-H2 were equally susceptible for the infection with MV-CD30 and 
VSV-CD30 in vitro (Figure 3.4). VSV-CD30 induced cell killing of both cHL cell lines (Figure 3.5). 
However, KM-H2 turned out to be more sensitive for oncolysis mediated by the infection with 
VSV-CD30 than L-428 in vivo (Figure 3.9, Figure 3.10). The classification of these two cHL types is 
probably not the reason for the different oncolytic effect observed in this study. L-428 belongs to 
the NSHL type while KM-H2 belongs to the MCHL type. However, the difference between both cHL 
types is mainly defined by histo-pathological conditions, while little is known about the molecular 
differences. It is more likely that characteristics of the tumor mouse model used here influenced 
the result of oncolytic activity of VSV-CD30. First, the tumor growth kinetic could influence the 
oncolytic activity of VSV-CD30. Growth of s.c. KM-H2 tumors was slower than growth of s.c. L-428 
tumors. A slower growing tumor could provide higher accessibility for an oncolytic virus than a 
faster growing one, because viral particle spread could be higher and reach all tumor sides. Second, 
the kinetic of oncolysis in both cell lines could influence the oncolytic activity of VSV-CD30. In vitro, 
viability of L-428 cells infected with VSV-CD30 was reduced faster than viability of KM-H2 cells 
infected with VSV-CD30. Faster oncolysis of L-428 may not be beneficial in a tumor mouse model. 
Initially infected cells would die too fast before they could release new viral particles to infect 
neighboring cells. In conclusion, slower oncolysis of KM-H2 cells may lead to a higher spread of 
VSV into the tumor tissue. CD30-targeted viruses encode for GFP as model transgene to follow up 
the infection process. To further optimize the therapeutic use of both viruses, therapeutic 
transgenes could be encoded in the viral genome. Expression of transgenes could benefit from a 
slower oncolysis in KM-H2 cells. 
Using the suitable tumor mouse model, there was no evidence for any impairment of the oncolytic 
activity by IFN suggesting that cHL may be compatible with VSV-mediated oncolytic activity. 
VSV-CD30 was highly active and prevented outgrowth of s.c. injected cHL cells after local as well as 
systemic application (Figure 3.16, Figure 3.18). In the tumor mouse model where cHL cells grew 
disseminated, a substantial reduction in tumor growth was observed at least for some mice (Figure 
3.22).  
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In contrast, ALCL cell lines were not susceptible for the infection with VSV-CD30, but for the 
infection with MV-CD30 (Figure 3.26, Figure 3.27). Most likely, ALCL cell lines tested here expressed 
a higher amount of type I IFN and therefore especially VSV-CD30 cannot infect those cells.  
An interesting aspect of using CD30 as viral entry receptor is, that CD30 present on the surface of 
HRS cells is cleaved by metalloproteinases resulting in sCD30 (Josimovic-Alasevic et al. 1989). 
Consequently, high serum levels of CD30 are used as diagnostic marker for cHL, ALCL and DLBCL 
(Schneider and Hübinger 2002). Interestingly, despite the release of sCD30, cHL tumor cells also 
release CD30 on extracellular vesicles (CD30-EV) for tumor-supporting communication with CD30L+ 
neighboring bystander cells (Hansen et al. 2014). sCD30 as well as CD30-EV both could potentially 
bind via the CD30-scFv to CD30-targeted viruses used in this thesis. In theory, this binding could 
lead to competition for CD30 binding sites and therefore reduce productive infection. For KM-H2 
cells used in this thesis, the release of sCD30 and CD30-EV into cell culture supernatant as well as 
into a Matrigel microenvironment is described in literature (Hansen et al. 2016). The plasma from 
NSG mice carrying a disseminated KM-H2 tumor was analyzed for the extend of any neutralizing 
effect on VSV-CD30. No competition of VSV-CD30 pre-incubated with NSG plasma was observed, 
while recombinant soluble CD30-Fc protein completely blocked infection (Figure 3.24). This could 
indicate that sCD30 was not present or concentrated highly enough to completely block VSV-CD30 
infection. However, presence and amount of sCD30 in NSG mice plasma were not quantified here.  
Nevertheless, the presence of sCD30 is only one possible explanation for the partial response to 
VSV-CD30 treatment observed in the KM-H2 multifocal tumor model. Based on the heterogeneous 
tumor growth pattern, some tumor niches could be better accessible than others for the infection 
with VSV-CD30. Furthermore, tumor cells could down regulate CD30 on their cell surface rather than 
releasing it as sCD30. When no CD30 is present as entry receptor, VSV-CD30 cannot infect cHL cells. 
Further analysis is needed to gain closer insights into the partial response of VSV-CD30 in this 
tumor mouse model. 
Apart from potential competition between sCD30 with VSV-CD30 for CD30 binding, Hansen el al. 
demonstrated, that CD30-EV positively contributed to the clinical efficacy of brentuximab vedotin 
(Hansen et al. 2016). They showed that brentuximab vedotin binds to CD30-EV and is then 
transported to the CD30L+, but CD30- surrounding bystander cells in the tumor microenvironment, 
Discussion 
 
77 
 
where it is internalized and becomes cytotoxically active. Accordingly it can be speculated that the 
CD30 targeted viruses investigated in this thesis, were transported via CD30-EV to CD30L+ bystander 
cells as well. The potential infection and killing of bystander cells is another interesting issue for 
further investigation. 
4.2 Increasing oncoselectivity of VSV 
To use VSV as an oncolytic virus, modifications of the virus to increase oncoselectivity and decrease 
neurotoxicity need to be made. Neurotoxicity is mainly associated with the VSV-G glycoprotein 
(Martinez et al. 2003; Clarke et al. 2007; Cooper et al. 2008). Therefore, pseudotyping VSV with 
heterologous glycoproteins and an additional layer of tumor-targeting could prevent neurotoxicity 
(Miest and Cattaneo 2014; Muik et al. 2014). 
For this purpose, a VSV-MV pseudotype was recently generated and used as background for 
VSV-CD30 analyzed in this thesis (Ayala-Breton et al. 2013). This first VSV-MV chimera did not 
contain an additional layer of tumor targeting. Since MV glycoproteins were inserted, MV-H protein 
could easily be used to retarget VSV-MV to tumor-associated antigens using the well-established 
MV retargeting concept. During the work on this thesis two examples of fully targeted VSV were 
published. 
In mid of 2015, Ayala Breton and colleagues described the first example of a fully replication-
competent, receptor targeted VSV. They generated a VSV-MV chimera retargeted to the Her2/neu 
receptor by displaying a scFv on MV-H. To analyze the effect of scFv affinity to its target, they 
rescued a panel of six VSV-Her2/neu viruses displaying Her2/neu-scFv that bind to the same Her2 
epitope but with different Kd values. They found, that a least a Kd of 10-8 M was required for the 
infection of Her2/neu+ tumor cells. All high affinity viruses with a Kd of >10-8 M were able to infect 
Her2/neu+ tumor cells and induced syncytia formation. In a s.c. tumor model of ovarian cancer, all 
high affinity viruses induced tumor shrinkage with no significant difference between them (Ayala 
Breton et al. 2015). The findings made there for the affinity threshold could suggest a high oncolytic 
effect for VSV-CD30 analyzed in this thesis, since its Kd value was determined to be 3.75 x 10-9 M 
(Friedel et al. 2015). 
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In 2017, parts of this thesis contributed to the generation of VSV-CD133 as a second example of a 
fully replication-competent, receptor targeted VSV (Kleinlützum et al. 2017). The chimeric VSV-CD133 
was generated as part of enhancing the oncolytic activity of the previously described MV-CD133 
against tumor stem cells (Bach et al. 2013). Different MV-CD133 variants were generated using arming 
techniques (MVSCD-CD133), receptor extension (MV-CD46/CD133) and the chimera between MV-CD133 
and VSV (VSV-CD133). To first verify safety of the newly generated viruses, CD133+ hematopoietic 
stem cells were infected. No productive infection of hematopoietic stem cells was observed, again 
most likely due to the high sensitivity of VSV against IFN. This is in line with observations made in 
this thesis regarding the infection of CD30+ activated T lymphocytes which were completely 
protected from infection. Oncolytic activity of the CD133-retargeted viruses was analyzed on a 
CD133+ hepatocellular carcinoma cell line in vitro. VSV-CD133 showed highest tumor cell killing 
within 48 hpi. In a s.c. tumor model of hepatocellular cancer, VSV-CD133 exhibited the strongest 
oncolytic activity and significantly prolonged survival of tumor bearing mice without any signs of 
neurotoxicity when administered intratumorally or intravenously. The data shown for the oncolytic 
activity of VSV-CD133 in vitro and in the s.c. tumor model of hepatocellular cancer are in line with 
the data shown for VSV-CD30 here in this thesis. For both retargeted VSV the antitumoral effect was 
more pronounced compared to retargeted MV in vitro and in vivo. In contrast, i.t. application of 
VSV-CD30 in cHL xenografts initially eliminated the tumor in two mice completely while VSV-CD133 
only induced delayed tumor growth in hepatocellular xenografts. Differences observed could be 
based on technical reasons. Application of VSV-CD133 was started when tumors already reached a 
size of 100 mm³ while in this thesis the injections started at a size of 50 mm³. In addition, VSV-CD133 
was only applied at a low dose of 4 x 106 TCID50 in total, while VSV-CD30 demonstrated here 
exhibited the best antitumoral effect at a high dose of 3 x 108 TCID50 in total. Furthermore, in none 
of the experiments the expression of target receptors was verified. Tumor resistance based on 
decreased amounts of target receptors could therefore also explain the differences observed here. 
To demonstrate the susceptibility of another CD133+ tumor type, primary glioma cells were infected 
with CD133-retargeted viruses. All viruses infected glioma tumor spheres and induced syncytia 
formation. However, 2-3 days after infection with VSV-CD133 tumor spheres started expanding 
again. Only MV-derived but not VSV-MV derived viruses were able to induce a continuous decrease 
in cell number. Since glioma spheres contained more than 90% CD133+ cells and VSV-MV did not 
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infect these cells, both aspects could be excluded. Therefore the hypothesis was made that cells 
became resistant through post-entry mechanisms e.g. an intact type I IFN response. Most cancer 
cell lines are described to have a deregulated IFN pathway. However there are many which have 
partial or complete intact IFN response (Stojdl et al. 2003; Dold et al. 2016). This has to be evaluated 
before using these cell lines for the treatment with oncolytic VSV. In an orthotopic glioma model 
using the same glioma tumor spheres, MV-CD46/CD133 and MVSCD-CD133 were most effective to clear 
tumor burden. Notably, VSV-CD133 caused fatal neurotoxicity in this tumor model, while the use of 
CD133 as receptor was excluded as being causative. This was surprising and somehow contradictory 
to the description of VSV-MV in 2013 (Ayala-Breton et al. 2013). There, VSV-MV was described to be 
highly attenuated to neurotoxicity due to the deletion of VSV-G. Similar findings were made when 
VSV was pseudotyped with glycoproteins from LCMV, which reduced neurotoxicity (Muik et al. 2011). 
As a conclusion, different virus types were identified as best treatment option for each tumor type. 
This data demonstrates that besides the rational tendency for VSV to be oncolytically more effective 
than MV, this cannot be generalized and has to be separately evaluated for each type of tumor. 
VSV-CD30 is now the third example of a receptor targeted VSV. Most importantly, in none of the 
in vivo tumor models investigated, including a multifocal growing tumor model for the first time, 
signs of neurotoxicity were observed. Severe symptoms of neurotoxicity by VSV-CD133 infection 
was only observed when applied directly into the brain. In the s.c. hepatocellular model, VSV-CD133 
proved to be safe after i.t. as well as i.v. application. However, if VSV-CD30 is inducing neurotoxicity 
when administered directly into the brain, needs to be considered in further safety studies before 
envisaging clinical studies. 
When using MV derived oncolytic viruses, the presence of neutralizing antibodies in MV vaccinated 
individuals is a major issue. Since VSV-MV is pseudotyped with MV glycoproteins, it likely would 
get neutralized too. There are multiple technologies to bypass the neutralization of MV or MV 
pseudotyped oncolytic viruses and increase serum stability after systemic application. One strategy 
describes the exchange of the surface proteins of MV since the immune neutralization is mainly 
associated with the glycoproteins. The glycoproteins from other paramyxoviruses like those of 
tupaia paramyxvirus (Miest et al. 2011; Hudacek et al. 2013) or Nipah virus are ideal candidates.  
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Glycoproteins from both viruses have a similar structure to those of MV in terms of separating 
fusion activity and receptor binding activity in two glycoproteins. Receptor binding proteins of both 
alternative paramyxoviruses allow the modification by inserting point mutations and fusion of a 
targeting ligand. In addition, glycoproteins from both viruses were recently tested for pseudotyping 
of lentiviral vector particles. They mediated specific gene transfer upon blinding of natural binding 
sites and fusion of a targeting ligand (Enkirch et al. 2013; Bender et al. 2016). Biological shielding of 
viral particles is another strategy to prevent neutralization. Ex vivo infected T lymphocytes (Ong et 
al. 2007) or mesenchymal stem cells (Mader et al. 2009; Mader et al. 2013) can be used as cell-based 
carriers in a “trojan horse” approach. 
4.3 Therapeutic application of receptor targeted oncolytic viruses 
With Imlygic, oncolytic viruses have reached marketing authorization while work on this thesis was 
ongoing. Authorized for the treatment of advanced melanoma patients, Imlygic is derived from the 
HSV-1 strain (Pol et al. 2016). Two genes for neurovirulence were inactivated to enhance the safety 
profile. Finally one cassette encoding GM-CSF was inserted to recruit and activate antigen-
presenting cells (Liu et al. 2003). However, in a phase III clinical trial the local injection in metastatic 
melanoma lesions improved the durable response rate only to 16% compared to sc. injected GM-
CSF alone (Andtbacka et al. 2015). Still the administration of Imlygic showed only mild adverse 
events like fatigue, chills, and pyrexia. In general, OVs are multi-mechanistic therapeutics. They can 
be considered as mono- or combination-therapy. Especially, combination with checkpoint inhibitors 
seems very promising.  
In a phase 1 clinical trial, the combination of Imlygic with the checkpoint inhibitor ipilimumab, 
which blocks the cytotoxic T lymphocyte associated antigen 4 (CTLA-4) improved the response rate 
from 18% (alone) to 39% (combination) (Chesney et al. 2016; Puzanov et al. 2016). In another phase 
1b trial, Imlygic was applied locally in combination with i.v. injected pembrolizumab, which blocks 
PD-1 on T lymphocytes achieving a complete response rate of 33% (Ribas et al. 2017). Intratumoral 
injection of Imlygic as an in situ vaccine attracted immune cells and therefore changed the tumor 
microenvironment in the injected lesions and increased T lymphocyte infiltration to turn it from 
“cold to hot” (Ribas et al. 2017). Both studies demonstrate that the oncolytic capacity of Imlygic can 
be boosted in combination with an immune checkpoint inhibitor. Besides Imlygic a chimeric 
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adenovirus (Enadenotucirev) in combination with pembrolizumab (ClinicalTrials.gov Identifier: 
NCT02636036) and a reovirus in combination with α-PD-1 (ClinicalTrials.gov Identifier: 
NCT02620423) are tested in phase I clinical trials (Breitbach et al. 2016).  
Other approaches to use oncolytic virotherapy as combination therapy is the combination with 
JAK/STAT inhibitors (Dold et al. 2016) or CAR (chimeric antigen receptor) T cells (Ajina and Maher 
2017). Both strategies benefit from changed tumor microenvironment induced by oncolysis. 
Oncolytic VSV-IFNβ-NIS is currently tested in different clinical trials. Interestingly, VSV-IFNβ-NIS is 
tested in a phase 1 study for treating patients with relapsed or refractory multiple myeloma, acute 
myeloid leukemia, or T cell lymphoma (ClinicalTrials.gov Identifier: NCT03017820). T cell 
lymphomas also include recurrent anaplastic large cell lymphoma. Therefore, VSV seems to have a 
natural preference for this tumor entity which was also analyzed in this thesis. In a two-part open 
label phase 1/2 study VSV-IFNβ-NIS is tested in treating patients with refractory solid tumors as i.t. 
administration in combination with the PD-L1 blocking agent avelumab (ClinicalTrials.gov Identifier: 
NCT02923466). This demonstrates that the oncolytic power of VSV can be boosted in combination 
with immune checkpoint inhibitors as well. 
All oncolytic viruses tested in clinical trials are non-receptor targeted viruses. Instead, most of them 
encode immune stimulatory transgenes. However, a variety of receptor targeted oncolytic viruses 
have been described as promising tools in cancer immunotherapy during the last decades in 
preclinical studies. Up to now, there is no clinical translation of receptor targeted oncolytic viruses. 
Initially, receptor targeting of oncolytic viruses was designed to increase the safety profile. 
However, Imlygic as the first oncolytic virus receiving marketing authorization was not designed to 
contain an additional layer of receptor targeting. It was tested to be safe and induced only mild 
adverse events. Currently, the need to improve safety based on restricting cell entry of oncolytic 
viruses is not a main focus of research. Most oncolytic viruses are oncoselective per se because of 
their natural tumor tropism. There is no additional benefit to include a secondary layer of selectivity. 
In fact, quite the contrary could result from receptor targeting. Tumors are highly heterogeneous 
and constantly evolving (Alexandrov et al. 2013). Therefore tumors can develop resistance against 
targeted therapies based on down regulation of the target receptor. Tumor cells that do no longer 
express the entry receptor cannot be infected any more. Besides local oncolysis a systemic 
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activation of the immune system is needed. Using a receptor targeted OV could potentially decrease 
the attraction of the immune system.  
However, in some cases, receptor targeted oncolytic viruses could be beneficial. For the treatment 
of disseminated cancers and metastasis only a systemic application can theoretically reach all 
tumor sites. Attempts at systemic delivery have shown limited success until now since the 
administered virus is immediately diluted in the circulating blood volume (Maroun et al. 2017). As 
consequence, extremely high doses are needed to achieve circulating titers. Here, the usage of 
receptor targeted viruses could be beneficial allowing for the administration of higher tumor 
destructive doses without toxicity to normal tissues. 
In a tumor mass where only few tumor cells are embedded in a changing immune cell infiltrate, 
potentially blocking accessibility, a receptor targeted OV could also be beneficial. Especially for cHL 
a CD30-targeted therapy approach using oncolytic viruses could be a new therapy approach to 
investigate. The targeting capacity of engineered MV glycoproteins was demonstrated on 
pseudotyped lentiviral vectors specific for CD105. CD105-LV discriminated between target cells and 
lymphocytes and selectively transduced CD105+ endothelial target cells in mixed cultures (Anliker 
et al. 2010). 
Particularly using VSV as a receptor targeted oncolytic virus has several advantages. In general 
Rhabdoviridae show a high safety profile, can be produced to high titers and can infect tumor 
vasculature (Breitbach et al. 2011). VSV-CD30 which was characterized in this thesis showed a high 
replication capacity, strong lytic properties and was able to reach disseminated tumor sides. Until 
now, manufacturing resulting in the production of low titers is one major limitation for a broad 
clinical application of many OVs. In the clinical trial analyzing MV-NIS 100 ml of virus suspension 
was infused into the patients to achieve a dose of 1011 TCID50 (Russell et al. 2014). In contrast, 
VSV-CD30 can be produced to higher titers out of supernatant of infected cells, representing a 
suitable virus stock for clinical trials. 
Based on the proof-of-concept study in this thesis, VSV-CD30 could also be equipped with immune 
stimulatory transgenes to further enhance its oncolytic capacity. Combining VSV-CD30 with other 
cancer therapeutics such as immune checkpoint inhibitors or CAR T cells could be another future 
option to be explored.  
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